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Abstract 
 
THE ROLE OF ADAM10, ADAM17, AND SPAG6 IN HUMORAL IMMUNITY AND 
SECONDARY LYMPHOID TISSUE ARCHITECTURE 
 
By Lauren Folgosa Cooley, Ph.D. 
 
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor 
of Philosophy at Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2015 
Director:  Daniel H. Conrad, Ph.D., Professor 
Department of Microbiology and Immunology School of Medicine 
 
 ADAM10, ADAM17, and SPAG6 contribute significantly to humoral immunity and 
secondary lymphoid tissue architecture.  ADAM10 and ADAM17 are two closely related 
zinc-metalloproteinases.  Through cleavage of their ligands CD23 and TNF, 
respectively, they greatly influence IgE production and secondary lymphoid tissue 
architecture maintenance.  Th1 prone WT strains initially exhibit increased ADAM17 and 
TNF yet reduced ADAM10 relative to Th2 prone WT strains.  In the absence of B cell 
ADAM10, a compensatory increase in ADAM17 and TNF cleavage is noted only in Th1 
prone C57Bl/6, not Th2 prone Balb/c.  B cell TNF homeostasis is important for 
maintaining secondary lymphoid tissue architecture.  We show for the first time that 
  
excessive B cell TNF production in C57-ADAM10B-/- lymph nodes contributes to loss of 
B/T segregation, increased HEV number and size, fibrosis, loss of FDC networks, and 
impaired germinal center formation.  Furthermore, B cell ADAM10, which enhances IgE 
production through CD23 cleavage, is shown to be a marker of Th2 susceptibility.  B cell 
ADAM10 is elevated in Th2 prone mouse strains and allergic patients compared to Th1 
prone controls and as B cell ADAM10 level increases, so does IgE production.  Lastly, 
the B cell profile of allergic patients is determined to be B cell 
ADAM10highADAM17lowTNFlow. 
 Furthermore, the mechanism underlying reduced class-switched antibody 
production in C57-ADAM10B-/- mice is explored.  C57-ADAM10B-/- B cells exhibit a B10, 
or IL-10 producing, phenotype, which is linked to reduced antibody production.  
Furthermore, increased Tregs noted in C57-ADAM10B-/- mice contributed to reduced 
class switched IgE production and disease parameters following a house dust mite 
airway inflammation challenge. 
SPAG6, a component of the central apparatus of the “9+2” axoneme, plays a 
central role in flagellar stability and motility.  Immune cells lack cilia, but the 
immunological synapse is a surrogate cilium as it utilizes the same machinery as 
ciliogenesis including the nucleation of microtubules at the centrosome.  We 
demonstrate that Spag6 localizes in the centrosome and is critical for centrosome 
polarization at and actin clearance away from the synapse between CTL and target 
cells.  Furthermore, improper synapse formation and function likely explains reduced 
CTL function and class-switched antibody production in Spag6KO mice.
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Section 1: The role of B cell ADAM10, ADAM17, and TNF in secondary lymphoid 
tissue archiecture and antibody responses. 
Chapter 1: Introduction to ADAM10, ADAM17, and their respective ligands in 
humoral immunity and secondary lymphoid tissue architecture 
1.1.1 Introduction to ADAM10 and ADAM17 
ADAMs Overview 
A disintegrin and metalloproteinases (ADAMs) belong to the metzincin 
superfamily of zinc dependent proteases and specifically to the M12B adamalysin 
protease subfamily along with structurally related snake venom reprolysins (SVR) and 
ADAM-thrombospondins (ADAMTS) [1,2].  All known ADAM proteins contain the 
following structural domains starting at the N terminus: (1) A pro-domain, which 
behaves as a chaperone for protein folding [3], and is thought to be cleaved 
intracellularly by pro-protein convertases during Golgi transit [4]; (2) A zinc dependent 
metalloprotease domain, which participates in substrate cleavage; (3) A 14 amino acid 
disintegrin loop binding domain, which confers substrate specificity [5]; (4) A cysteine 
rich ligand binding domain; (5) An EGF-like domain, which is absent in ADAM10 and 
ADAM17; (6) A transmembrane domain, which differentiates ADAMs from other 
metzincin family members; and (6) A cytoplasmic tail domain that varies widely in length 
and sequence between ADAM members (Figure 1).  
Unlike other metzincin family proteases such as SVR, ADAMTS, and matrix 
metalloproteases (MMPs), ADAMs are unique in that they are catalytically active while 
membrane bound.  Because they are membrane bound, ADAMs mediate ectodomain 
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shedding of mainly type 1 and type 2 transmembrane proteins.  This ectodomain 
shedding can lead to downregulation of signaling events and/or effect autocrine and 
paracrine signaling through release of soluble mediators [6].  Furthermore, they 
participate in regulated intramembrane proteolysis (RIP), which requires receptor-ligand 
interaction [7].  ADAM-mediated proteolysis is both constitutive and inducible and can 
be modulated by many factors including: intracellular calcium levels, membrane lipid 
composition, ease of removal of the inhibitory pro-domain, and post-translational 
modification of the cytoplasmic tail domain [8].  Lastly, the number and function of each 
ADAM protein varies between species. For instance, the human genome contains 25 
ADAM genes whereas the mouse has 37.  Furthermore, which ADAMs are catalytically 
active may vary between species and some ADAMs, specifically in humans, are thought 
to play a role in protein folding rather than catalysis because the critical zinc binding 
active site is absent [1].  Overall, catalytically active ADAMs, termed sheddases, share 
the following zinc-binding consensus sequence: (HEXGHXXGXXHD)[9].   
ADAM10 
ADAM10 was initially characterized in 1996 through study of its homolog in 
Drosophila, Kuzbanian (kuz).  Studies of kuz deficient embryos revealed its critical 
importance in the development of the peripheral and central nervous system (CNS) [10].  
Cloning and sequencing of kuz demonstrated disintegrin and metalloprotease domains 
homologous with bovine metalloprotease (BMP), which would later be called ADAM10 
[10].  Subsequent studies regarding nervous system defects in the absence of ADAM10 
revealed the key role of ADAM10 in Notch signaling [11].  Given the importance of 
Notch in early development, ADAM10 deficient embryos experience early death at 
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embryonic day 9.5 due to defects in CNS and cardiovascular development [12]. 
Therefore, conditional knockout models have typically been used to study ADAM10 in 
vivo.   
Regulation and trafficking of ADAM10 to its sites of action is still poorly 
understood although some players have been identified.  ADAM10 is ubiquitously 
expressed and is synthesized in the endoplasmic reticulum (ER) in an inactive pro-form.  
Tetraspanin 15 (TSPAN15) helps to accelerate ER exit to the Golgi [13].  Tetraspanins 
are termed “molecular facilitators” or chaperones that modulate the formation and 
stabilization of signaling complexes [14,15].  During Golgi transit, furin and pro-protein 
convertase (PC7) remove the inhibitory, pro-domain from ADAM10 [16].  TSPAN15 
remains with ADAM10 throughout this process and helps with the integration and 
stabilization of ADAM10 into the membrane and further helps ADAM10 gain access to 
substrates.  Furthermore, ADAM10 is known to bind TSPAN12, which has been shown 
to aid in ADAM10 maturation.  siRNA ablation of TSPAN12 reduced ADAM10 
maturation and its shedding of amyloid precursor protein (APP) [17].  While it is well 
known ADAM10 cleaves membrane bound substrates from the plasma membrane, 
there is also evidence that ADAM10 cleaves in the endosomal pathway and is more 
catalytically active at acidic pH [18].  Following internalization of ADAM10 and its 
substrate, they are trafficked through the endosome into multivesicular bodies where 
shedding occurs and both are then sorted into exosomes [19].  Exosomes are 30-
100nm, membrane-containing vesicles that are released from cells, express MHC and 
integrins, and may be able to present antigen to T cells [19,20].  Furthermore, Tousseyn 
et al. showed that ADAM10 itself can be processed by ADAM9, ADAM15, and γ-
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secretase, releasing the ADAM10 intracellular domain, which can modulate gene 
transcription [21].  One direct consequence of ADAM10 processing was described by 
Arima et al. in human prostate cancer progression.  ADAM10 translocation to the 
nucleus occurred more frequently in prostate cancer cells compared to benign prostatic 
hyperplasia (BPH), which expressed predominantly membrane ADAM10 [22].     
Little is known about ADAM10 regulation following pro-domain cleavage.  
Following ADAM10 activation, in vitro ADAM10 activity can be inhibited by tissue 
inhibitors of metalloproteases (TIMP)-1 and TIMP-3 [23].  Additionally, its proteolytic 
activity is enhanced by calcium influx, retinoic acid receptor signaling, PKC signaling, 
cholesterol depletion, kainite receptor signaling and N-glycosylation [24–29].  
Regulation of ADAM10 activity is critical for maintaining a homeostatic release of 
substrates.  A critical ADAM10 substrate for both organ system development as well as 
lymphocyte development is Notch receptor(s).  While ADAM10 has many substrates 
several important ones for this discussion will be CD23 and TNF.  The low affinity IgE 
receptor, CD23, regulates IgE production [30]; and, TNF is a pro-inflammatory cytokine 
that is also important for maintaining secondary lymphoid tissue architecture (section 
1.1.6) [31–34].  Lastly, ADAM10 participates predominately in cis-cleavage but has 
been shown in certain instances to cleave substrates in trans [35].        
ADAM17 
 TNF is a key pro-inflammatory cytokine, which exists as a 26kDa transmembrane 
protein (mTNF) and a 17kDa soluble molecule (sTNF) [36].  Given its critical 
importance, many groups aimed to discover the protease responsible for its cleavage.  
In 1997, two groups simultaneously described a new ADAM protease, ADAM17, which 
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was responsible for the cleavage of pro-TNF [37,38].  Its gene is located on 
chromosome 2p25 in humans and chromosome 12 in mice.  Similar to ADAM10, it is 
ubiquitously expressed in many cells and tissues and is critical during development [37].  
Although ADAM17 is most closely related in structure to ADAM10, as both lack the 
EGF-like domain found in other ADAMs, they still only share 30% homology [39].       
 Data on the overall regulation and trafficking of ADAM17 is sparse and often 
contradictory.  ADAM17 has an inhibitory pro-domain that is cleaved similar to ADAM10 
by furin in the trans-Golgi network [40].  While pro-domain removal is critical for 
enzymatic activity, it is not required for ADAM17 transport to the plasma membrane 
[41].  Furthermore, immunohistochemistry evidence suggests that active ADAM17 
exists in the perinuclear region with very little on the plasma membrane [40], but many 
still believe cleavage is mostly restricted to the plasma membrane.  Whereas 
tetraspanins are important for ADAM10 trafficking through the ER and Golgi, it is a 
rhomboid protein, iRhom2, which is critical for ADAM17 trafficking [42,43].  iRhom2 
escorts ADAM17 from the ER, through the trans-Golgi network, and ultimately to the 
site of ligand cleavage.  In the absence of iRhom2, furin-mediated proteolysis of 
ADAM17 and trafficking to the cell surface does not occur [42,43].   Post-translational 
modifications of ADAM17 protein include phosphorylation of ADAM17 residues, 
specifically serine and threonine.  Currently, there is conflicting evidence about which 
residues are critical for ADAM17’s activity and whether phosphorylation or de-
phosphorylation of those residues enhance activity.  One example is ADAM17 
modification following phorbol ester (PMA) stimulation.  PMA is known to stimulate 
ADAM17 activity through phosphorylation events, but conflicting reports have named 
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both threonine 735 and serine 819 as the critical phosphorylation site [44,45].  In 
general, however, it is accepted that various stimuli may cause a differential 
phosphorylation or de-phosphorylation pattern but exact mechanisms are unknown.  
Lastly, ADAM17 activity is inhibited endogenously by TIMP-3 and has been shown to 
have several other binding partners, including α5β1 integrin, whose roles in modulating 
ADAM17 activity are still under investigation [39]. 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic of ADAM10 and ADAM17. 
ADAM10 and ADAM17 are membrane bound proteases and are composed of the 
following domains: (1) zinc dependent metalloproteinase (yellow); (2) disintegrin (red); 
(3) cysteine-rich (green); (4) transmembrane
ADAM10 and 17 mediate cleavage of cytokine
signaling events through receptor cleavage.    
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 (orange); (5) short cytoplasmic tail
s and growth factors as well as initiate 
 
 
 (black).  
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1.1.2 Introduction to secondary lymphoid tissues 
Secondary lymphoid tissues are primary sites of adaptive immune responses and 
consist of lymph nodes (LN), spleen, tonsils, Peyer’s patches (PP), bronchiolar-
associated lymphoid tissues (BALT), gut-associated lymphoid tissues (GALT), and 
mucosa-associated lymphoid tissues (MALT).  They are located strategically throughout 
the body in order to efficiently alert immune cells to the presence of foreign antigen and 
allow a structured framework for their encounter [46–49].  While lymphocytes and other 
immune cells are mobile and migrate in and out of secondary lymphoid tissues, their 
architecture is tightly regulated and organized.  During embryogenesis, secondary 
lymphoid tissues begin to develop when hematopoietic lymphoid tissue inducer cells 
(LTi), expressing lymphotoxin αβ (LT), and mesenchymal cells, expressing LTβ 
receptor, interact.  Induction of LT signaling in mesenchymal cells triggers their 
differentiation into stromal organizer cells and induces homeostatic chemokine 
expression, such as CXCL13, CCL19, and CCL21, that aid in migration of naïve 
lymphocytes [47,50,51].  The critical importance of LT is demonstrated in LT-deficient 
mice, which lack peripheral LN, PP, and demonstrate severely disrupted splenic 
architecture. 
Secondary lymphoid tissues are highly organized tissues, which is thought to aid 
in efficient response to foreign antigen.  LNs, for instance, have an afferent vasculature 
supply, which brings antigen presenting cells (APCs) and foreign antigen into the LN 
marginal sinus.  Lymphocytes and APCs can also access the LN through high 
endothelial venules (HEVs) found in the paracortex.  The LN is divided into a cortex and 
medulla.  The cortical region consists of (1) the outer cortex, or B cell zone, which 
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contains resting, primary B cell follicles; and, (2) the paracortex, where T cells reside.  
The medulla is divided into medullary chords containing macrophages and plasma cells 
and medullary sinuses, which drain immune cells into efferent lymphatics.  Splenic 
structure, while reminiscent of LN structure, varies in several ways [47,51].  The spleen 
is divided into red and white pulp.  The red pulp is responsible for the filtration of red 
blood cells (RBCs) and removal of damaged or aged RBCs from circulation [47].  The 
white pulp consists of periarteriolar lymphoid sheaths (PALS), which are comprised of a 
central arteriole surrounded by a T cell rich compartment encircled by B cell follicles 
containing FDCs [47,49].  The red and white pulp is separated by the marginal zone 
(MZ), which holds MZ macrophages and MZ B cells (MZB). MZB development and 
maintenance requires CD19, Notch2, and ADAM10 protein expression and signaling 
[52–54].  Briefly, B cell specific Notch2-/- mice fail to develop MZB as do B cell specific 
ADAM10 deficient mice.          
B and T cells home to their respective zones due to chemokine gradients.  B 
cells express CXCR5, which binds CXCL13 causing migration to the follicle.  It is 
thought that follicular dendritic cells (FDCs), which reside in the B cell follicle, release 
CXCL13 [55].  B cells typically enter the LN through HEVs located in the T cell zone 
before migrating to the B cell follicle; however, they may also enter through the afferent 
lymphatic system.  Fibroblastic reticular cells (FRC) reside in the T cell zone and 
release CCL19 and CCL20, which bind CCR7 on naïve T cells and dendritic cells (DC) 
[56].  Thus, CCL19/20 interaction with CCR7 is important for both T cell homing to the 
paracortex as well as DC migration to lymphoid tissues.  When dendritic cells encounter 
antigen in the periphery, the antigen is processed and presented in major 
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histocompatibility complex class II (MHCII) and co-stimulatory molecules, CD80/86, are 
upregulated.  When the DC enters the paracortex, MHCII plus antigen is recognized by 
the TCR on antigen-specific CD4+ T cells and CD80/86 interacts with T cell CD28 to 
provide the second signal for activation.  Furthermore, the cytokine environment will 
cause CD4+ T cell differentiation into various T helper (Th) cell classes (see section 
1.1.5) [57,58].       
1.1.3 B cell activation 
B cells are responsible for the humoral arm of the adaptive immune system and 
produce high affinity antibody against foreign antigens.  B cells initially express 
membrane bound immunoglobulin, also known as the B cell receptor (BCR), which 
confers specificity to a particular antigen.  The BCR complex is comprised of cell 
surface immunoglobulin made of a heavy and light chain as well as antigen-nonspecific, 
invariant proteins Igα and Igβ, which express immunoreceptor tyrosine-based activation 
motifs (ITAMs) [59,60].  Activation of B cells requires cross-linking of the BCR, thus 
complex, multivalent antigens are stronger B cell activators because they allow 
extensive receptor crosslinking.  Following crosslinking, ITAMs are phosphorylated by 
Src family tyrosine kinases (Lyn, Fyn, and Blk) followed by activation of Syk tyrosine 
kinase.  Syk then phosphorylates its targets including BLNK, CD19, and PLC-γ, which 
activates Ca2+ and MAP kinase signaling.  Ultimately, NFκB, NFAT, and AP-1 
transcription factors are activated and lead to downstream activation of genes required 
for B cell proliferation and differentiation.  BCR signaling is further modulated by a B cell 
co-receptor complex comprised of CD21, CD19, and CD81 [59–61]. In addition to 
antigen induced signaling through the BCR, B cells process and present antigen in 
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MHCII for CD4+ T cell recognition and receive cytokine signals that further affect their 
activation.    
T dependent responses 
Protein antigens are considered T cell or thymus dependent (TD) antigens as B 
cells require T cell help for activation.  Antigen-bound B cells encounter T cells at the T-
B border in secondary lymphoid tissues.  A cognate interaction between antigen-specific 
B and T cells occurs as B cells process and present antigen in MHCII to CD4+ T helper 
cells.  Additionally, CD40 receptor on B cells engages CD40 ligand (CD40L) on T cells 
and T cells deliver cytokines signals such as IL-4, IL-5, IL-6, and IL-21, which help 
shape humoral responses.  Following this cognate interaction, B cells proliferate or 
clonally expand in a primary, extra-follicular focus at the T-B border and form antibody-
synthesizing plasmablasts, which have both membrane bound and secretory antibody 
(Ig).  At this point, B cells commit to an extra-follicular or germinal center (GC) pathway.  
It is not clear what causes commitment to either pathway.  Paus et al. proposed that B 
cells with highest antigen affinity initially will differentiate along the extra-follicular 
pathway into plasma cells [62].  These extra-follicular origin plasma cells tend to be 
short-lived, non-migratory, and primarily secrete IgM [63,64].  The germinal center 
pathway is discussed in section 1.1.4.           
T independent responses 
B cell responses to T-independent (TI) antigens do not require T cell help and is 
why antibody responses exist in humans and mice with T cell deficiencies. TI antigens 
are subdivided into TI type 1 (TI-1) and TI type 2 (TI-2) antigens [65].  TI-1 antigens, 
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also called B cell mitogens, can activate immature or mature B cells and intrinsically 
induce B cell division.  They typically cause polyclonal B cell activation, especially at 
high concentration.  A classic TI-1 antigen is lipopolysaccharide (LPS) [66].  TI-2 
antigens can only activate mature B cells to make IgM and are thought to do so by 
cross-linking many BCRs on mature, antigen-specific B cells.  B cells responding to TI-2 
antigens further require a cytokine signal called B cell activating factor (BAFF) in order 
to induce class-switching to IgG [67,68].  TI-2 antigens are highly repetitive 
polysaccharides and help confer immunity to encapsulated bacteria [65].  B1b B cells 
(B220+CD23-CD11b+CD5+) and MZB are thought to make antibody by this mechanism 
[69].  In general, both TI-1 and TI-2 antigens are thought to be poor at generating B cell 
memory responses; but; it has been reported that LPS and polysaccharide antigens can 
induce a memory response in rats [66].   
1.1.4 Germinal Centers 
Structure, formation, and maintenance 
 Once B cells are activated at the T-B border, some will migrate to the follicle via 
CXCL13/CXCR5 interactions and form a germinal center (GC) [55,57].  A GC is a 
specialized microenvironment within the follicle where B cells rapidly divide and undergo 
class switch recombination, somatic hypermutation, and affinity maturation to 
strengthen antibody binding.  The GC can be divided into the mantle zone, dark zone 
and light zone [57,58]. The mantle zone includes resting B cells that are pushed to the 
periphery by the rapidly proliferating B cell population as well as recirculating B cells.  
The dark zone consists of rapidly dividing B cells, or centroblasts, that undergo somatic 
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hypermutation and class switch recombination [70].  The light zone contains FDCs, T 
follicular helper cells (Tfh), and B cells (centrocytes) undergoing affinity maturation 
[58,71].  B cells can proliferate albeit to a lesser extent in the light zone; but, this is 
considered a site of massive apoptosis for B cells that lose antigen specificity.  
Furthermore, while B cells classically move from dark to light zone, they can also move 
from light to dark [72].  GCs are present for 3-4 weeks after antigen exposure with their 
peak response occurring around day 15.   
 Other factors that are critical for GC formation and maintenance are Bcl6 and IL-
21 [73–76].  Bcl6 is a transcriptional repressor found in both B cells and Tfh cells [73–
75].  Bcl6 is required to prevent apoptosis induced by DNA damage that occurs during 
somatic hypermutation and class switch recombination [77].  Furthermore, Bcl6 is 
thought to prevent differentiation of B cells into plasma cells until sufficient antibody 
affinity is achieved [78].  Within the germinal center activated FDC produce IL-6, which 
is known to induce Bcl-6 expression [79,80].  Lastly, IL-21 is known to play a critical role 
in GC formation and antibody responses as IL-21 or IL-21 receptor deficient mice 
exhibit significantly reduced antigen-specific IgG [81] and decreased GC persistence 
[76].  IL-21 is not required, however, for memory B cell formation [76].  IL-21 induces 
STAT3 signaling, which is essential for generation of IgG1 secreting cells [82]. 
 Lastly, sphingosine 1-phosphate receptor 2 (S1P2) is critical for homing and 
retention of cells in the germinal center.  First, B cells require S1P2 to stay within the GC 
niche [83].  Furthermore, Moriyama et al. described that Tfh cells within the GC express 
high levels of S1P2 [84]. S1P2 deficient mice had reduced Tfh retention in GCs and it is 
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thought that S1P2 and CXCR5 work cooperatively to traffic Tfh cells and retain them in 
the GC [84].        
Somatic hypermutation and class switch recombination 
 Both somatic hypermutation (SHM) and class switch recombination (CSR) occur 
within the dark zone of the GC.  The overall goal of SHM is to introduce mutations into V 
regions of the immunoglobulin gene in the hopes to increasing antibody specificity.  
While antigen specificity is not altered during class switch recombination, the class of 
antibody (e.g. IgM, IgG) changes, which determines its function as well its distribution 
throughout the body.  Activation-induced cytidine deaminase (AID) is expressed only in 
B cells and drives both SHM and CSR [71].  AID deaminates cytidine to form uridine in 
switch regions of the immunoglobulin gene.  This event triggers recruitment of base 
excision repair machinery (BER) including uracil-DNA glycosylase (UNG), which 
removes uridine.  These mutations alter the amino acid sequence and may (1) disrupt 
antibody structure; (2) cause reduction or loss of antibody specificity; or (3) improve 
antibody specificity [65,71].  Because SHM can increase antibody specificity, it is said to 
drive affinity maturation.  After AID and UNG steps, CSR further requires 
apurinic/apyrimidinic site endonuclease 1 (APE1) to introduce single strand nicks on 
both DNA strands, which leads to staggered double strand nicks.  Double strand break 
repair machinery (DSBR) is then recruited and removes the damaged DNA region, 
ultimately driving recombination of the VDJ with a C region (e.g. Cµ, Cγ1, Cε), which 
determines the isotype [85].    
Affinity maturation and high affinity B cell selection 
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 B cell selection contributing to affinity maturation is still a very controversial topic.  
Many mechanisms have been proposed for B cell selection post GC including (1) 
competition for FDC bound antigen; and, (2) competition for Tfh help [86].  The ultimate 
goal of B cell selection is to purge the germinal center of low affinity B cells and only 
allow B cells with high affinity Ig to survive.  In the classical model, B cells compete for 
binding to FDC, which have retained antigen. B cell fate is dependent on the strength of 
interactions with the antigen.  If BCR signaling is too weak, apoptosis occurs [87].  If 
BCR signaling is sufficient, the B cell survives and presents antigen to Tfh cells, which 
stimulate B cell differentiation into plasma cells or memory B cells.  Critics of this theory 
state that this theory alone does not account for the robustness of affinity maturation 
that is observed [88].  An alternate theory states that Tfh cells do not only provide 
differentiation signals at the end but also play an important role in the selection process 
[57,88].  While the topic is still controversial, high affinity B cells ultimately leave the GC 
following selection and differentiate into plasma cells or memory B cells.             
1.1.5 Th differentiation and associated antibodies 
When naïve CD4+ T cells leave the thymus, they are capable of differentiating 
into several different Th subtypes depending on the cytokine environment, the antigen 
to which the immune system is responding, and cell signaling events that upregulate 
transcription factors characteristic of a particular subtype [89].  For the purposes of work 
described herein, Th1 and Th2 differentiation are highlighted. 
Th1 differentiation occurs during infection with intracellular pathogens and when 
activated inappropriately, can result in autoimmunity.  IFNγ and IL-27 (IL-12 family 
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cytokine) initiate STAT1 and STAT1/4 signaling, respectively, leading to T-bet (Th1 
transcription factor) upregulation, which together with Runx3 increases transcription of 
more IFNγ [90].  Furthermore, T-bet and Runx3 silence the IL-4 gene and GATA3, thus 
inhibiting Th2 differentiation [89].  IgG2a/c and IgG2b are considered “Th1” isotypes and 
are increased by Th1 promoting cytokines such as IFNγ and IL-12 [91,92].  Th2 cells 
respond to extracellular parasite infection and are required for the induction and 
persistence of asthma and allergy [93,94].  Th2 differentiation requires IL-4 and IL-2 
signaling.  IL-4 induces STAT6, which drives GATA3 transcription factor expression.  
GATA3 has three critical actions.  First, it suppresses Th1 differentiation by 
downregulating STAT4.  Second, it enhances Th2 cytokine production (e.g. IL4, IL5, 
IL9, IL13, IL10, IL25). Third, it aids in the proliferation of Th2 cells [95,96].  IL-2 activates 
STAT5.  STAT5 and GATA3 bind different sites of the IL-4 gene and their coordinated 
activity is required for IL-4 production [97].  IgG1 and IgE are considered “Th2” isotypes 
as they are increased by Th2 cytokines such as IL-4 [91–93].        
The Th1/Th2 paradigm is classically attributed to differences in CD4+ T cell 
response, with B cells considered bystanders waiting for the T cell cytokine signal.  
Allergic diseases, such as asthma and allergic rhinitis, are skewed towards a Th2 
phenotype whereas rheumatoid arthritis and other autoimmune disease are skewed  
toward Th1 [98].  Furthermore, different mouse strains are considered Th1 or Th2-prone 
based on their propensity to make “Th1” or “Th2” classes of antibody post immunization.  
Classic Th1 (such as C57Bl/6 and SJL/J) and Th2-prone (such as Balb/c and A/J) 
strains were characterized as high (Balb/c, A/J), intermediate (C57Bl/6), and low (SJL/J) 
IgE responders following immunization [99].  Differences in their antibody production 
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were attributed to differences in CD4+ T cell signal.  Whether B cells from Th1 or Th2-
biased mouse strains have intrinsic differences that may affect IgE production, such as 
varied ADAM10 and ADAM17 levels, has never been elucidated and is discussed 
herein.                   
1.1.6 ADAMs 10 and 17 ligands in maintaining secondary lymphoid tissue 
architecture and humoral responses 
TNF Family Cytokines 
TNF and its closely related family members, lymphotoxin alpha (LTα) and beta 
(LTβ), have been extensively studied in the development and maintenance of 
secondary lymphoid tissue architecture.  Lymphotoxin is a trimeric cytokine and typically 
exists as a secreted homotrimer, LTα3, or a membrane bound heterotrimer, LTα1β2, on 
activated B, T, and NK cells [100].  LTα deficient mice lack lymph nodes and Peyer’s 
patches and exhibit abnormal splenic architecture including loss of B cell/T cell 
segregation and a complete absence of FDC networks, germinal centers, and MZB 
[101,102].  LTα as a soluble homotrimer (LTα3) is also known to play an integral role in 
lymphoid organization including B cell/T cell segregation by binding to the TNF receptor, 
p55TNFR-1 [103].  LTβ deficient mice, however, experience more mild disruption as 
they retain mesenteric and cervical lymph node development and maintain B cell/T cell 
segregation, FDC networks, and germinal center formation in spleen [104].  There is 
currently only one report that states that membrane bound LTα1β2 heterotrimer on T 
cells is cleaved by ADAM17 in vitro and this cleavage is blocked by the ADAM17 
inhibitor, TAPI-1[100].  They specifically were looking for a mechanism underlying 
increased LTα1β2 in the serum and synovial fluid of rheumatoid arthritis patients [100].  
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To date, there are no studies analyzing the relationship between ADAM17 and LTα1β2 
in maintaining secondary lymphoid tissue architecture.  
ADAM10 and ADAM17 are closely related ADAMs; therefore, many questions 
have been raised about their functional redundancy under physiologic conditions as well 
as in various genetically manipulated animal models.  While ADAM17 is the principle 
sheddase of TNF under physiologic conditions, ADAM10 is known to cleave TNF, 
especially in the absence of ADAM17 [105].  Mezyk-Kopec et al. further demonstrated 
that in ADAM17 deficient mouse embryonic fibroblasts, ADAM10 increases and 
ADAM10 dependent cleavage of TNF is seen [106].  With regards to TNF and 
secondary lymphoid tissue architecture, global TNF deficient mice exhibit disorganized 
follicular dendritic cell (FDC) networks, aberrant germinal centers, and lack of splenic B 
cell follicles [32].  Furthermore, in a B cell specific mutant model, which expresses a 
non-cleavable form of mTNF, abnormal B cell/T cell localization with loss of a proper 
cortico-medullary junction, reduced germinal center formation, impaired FDC network 
development, and reduced IgG production against T dependent antigens was seen [34].  
Thus, adequate levels of B cell produced sTNF is critical for maintaining secondary 
architecture in the lymph node, spleen and Peyer’s patches and for optimal antibody 
responses [34].  Interestingly, B cell specific ADAM10 deficient mice exhibit similar 
alterations in immunized and naïve lymph nodes [31,107], which is described herein.  
While lack of B cell sTNF is known to lead to phenotypic alterations, work herein 
demonstrated for the first time that excessive B cell sTNF also leads to defects in 
secondary lymphoid tissue architecture.   
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  Lastly, B cell TNF production can affect downstream antibody production.  First, 
given that proper secondary lymphoid tissue architecture is critical for optimal germinal 
center formation and antibody production, B cell TNF homeostasis is critical for proper 
antibody responses [32–34].  Furthermore, Frasca et al. demonstrated that increased B 
cell TNF production is a key factor implicated in B cell aging, which ultimately curtails 
class-switched antibody production [108].  Therefore, both excessive and too little B cell 
TNF has negative consequences on optimal antibody production.         
ICOSL 
 ICOS is inducible costimulator molecule, which is a member of the CD28/CTLA-
4/B7 immunoglobulin superfamily. It is found on activated T cells and binds ICOSL, 
which is found on B cells, DCs, as well as non-immune cells [109].  While not classically 
discussed as a co-stimulation signal needed for B cell activation, it is known that ICOS-
/- [110] and ICOSL-/- [111] mice have defects in germinal center formation and antigen-
specific antibody production.  Marczynska et al. demonstrated that ADAM17 regulates 
ICOSL cleavage in vitro [112].  Treatment of WT B cells with PMA resulted in cleavage 
of ICOSL.  B cells with significantly reduced ADAM17 expression (ADAM17ex/ex B cells), 
however, exhibited reduced ICOSL cleavage following PMA stimulation [112].  To 
determine if ADAM17 directly cleaved ICOSL, they performed purified recombinant 
enzyme studies and found that ADAM17 does not directly cleave ICOSL, but instead is 
indirectly involved in the downregulation of surface ICOSL [112].  Following in vivo 
immunization, furthermore, ADAM17ex/ex mice have increased germinal center B cells 
and plasma cells in draining LN, increased total and antigen specific IgG1 and IgG2a, 
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and draining LN hyperplasia with normal architecture [112].  Therefore, decreased 
ADAM17 and increased surface bound ICOSL lends to increased antibody production. 
 Furthermore, ICOS-ICOSL interactions are critical for the generation and 
maintenance of T regulatory cells (described in 1.1.7).  Zheng et al. noted that blockade 
of ICOS-ICOSL interactions in vitro impaired Treg induction as well as expression of 
CTLA-4 and other mechanisms characteristic of Treg suppression [113].  Furthermore, 
Redpath et al. described that ICOS deficiency led to FoxP3+ Treg apoptosis, impaired 
IL-10 production, and increased Th2 responses in the intestine during helminth infection 
[114].  It is not clear, however, if ICOSL must be membrane-bound or soluble to induce 
Tregs through ICOS receptor.  Overall, given the importance of ADAM17 in regulating 
ICOSL levels, ADAM17 may indirectly affect Treg induction and function by controlling 
ICOSL levels.  Specifically, increased B cell ADAM17 would lead to increased soluble 
ICOSL, which may cause increased Treg induction through binding to ICOS receptor.     
CD23, IgE, and asthma 
CD23 is a unique Fc receptor as it is a type 2 transmembrane protein and a 
member of the calcium dependent (C type) lectin family.  It exists in two isoforms, 
CD23a and CD23b, and has three domains: (1) IgE interacting carboxy terminal 
domain, (2) stalk regions, and (3) a short cytoplasmic tail [115].  Surface CD23 levels 
can be increased in an IL-4 or IL-13 dependent manner [115].  In humans, peripheral 
blood mononuclear cells stimulated with IL-4 exhibit increased CD23 shedding and IgE 
production whereas treatment with anti-CD23, which prevents its cleavage, inhibits IgE 
production [116].  Several enzymes had been implicated in the cleavage of CD23 
including ADAM8 [117] and other hydroxymate sensitive metalloproteinases [118], but 
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ADAM10 was determined by Weskamp et al. in a series of loss and gain of ADAM 
protease function experiments to be the principle sheddase of CD23 in B cells [30].  
Once cleaved from the surface, sCD23 enhances IgE production by an unknown 
mechanism. Several models exist that attempt to explain this relationship including: (1) 
High levels of IgE stabilize mCD23 and reduce further IgE production while allergen 
proteases and anti-CD23 stalk monoclonal antibodies destabilize CD23, increase its 
proteolysis, and increase IgE production [115]; and, (2)  sCD23 crosslinks membrane 
IgE and CD21 resulting in increased IgE production [119].  This relationship between 
ADAM10, CD23, and IgE has since ignited much interest in the asthma and allergy 
fields regarding the use of ADAM10 or CD23 cleavage inhibitors as a mechanism to 
prevent IgE synthesis. 
Asthma is a chronic airway disease characterized by wheezing, cough, shortness 
of breath, chest tightness, and “asthma attacks” caused by obstruction in airflow.  In the 
United States, prevalence has increased since 2001 with children and African 
Americans having the highest incidence [120].  Unfortunately, this report did not 
distinguish between the incidence in allergic and non-allergic asthma.  Another 
community based clinical study of Danish adolescents and adults, reported that allergic 
asthma represents three out of five asthma cases.  Furthermore, they reported that 
allergic asthma patients had greater AHR compared to non-allergic asthma patients 
[121].   Allergy and allergic asthma are considered classic Th2 diseases with IgE as the 
predominant antibody class coordinating the response.  IgE levels are tightly regulated 
and of all Ig classes have the lowest levels in vivo [122].  Interestingly, IgE can detect 
very low levels of antigen and is often the first to detect foreign particles in areas of 
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interface with the environment.  When these foreign particles are innocuous, such as 
pollen, cat dander or peanut proteins, IgE moves from beneficial to potentially life 
threatening.  IgE mediates allergic responses from mild to severe reactions, such as 
allergic rhinitis, atopic dermatitis, urticaria, asthma, and anaphylactic shock [123].  
IgE participates in the immune response in one of three ways.  First, antigen 
specific IgE binds the high affinity IgE receptor, FcεRI, on mast cells (MCs) or basophils 
where it can persist for up to 21 days waiting to bind to antigen, cross-link the FcεRI and 
degranulate the MC [124,125].  Degranulation results in the release of many mediators 
including (1) histamine, which increases vascular permeability and smooth muscle 
contraction; (2) MC enzymes, such as tryptase and chymase, which cause connective 
tissue and matrix remodeling; (3) cytokines, such as IL-4, IL-13, IL-5, and TNF, which 
amplify the Th2 response, recruit eosinophils, and promote inflammation, respectively; 
and (4) lipid mediators, such as leukotrienes, which increase vascular permeability, 
stimulate mucus secretion, and cause smooth muscle contraction [126].  While 
histamine, MC enzymes, and some TNF are stored as preformed mediators and 
released immediately, the others are synthesized following IgE/ FcεRI cross-linking and 
are important for the late-phase reaction [123,127].  Second, circulating IgE can bind to 
its antigen creating an IgE-immune complex.  IgE immune complexes are picked up by 
circulating follicular (FO) B cells by binding to CD23, the low affinity IgE receptor 
(FcεRII) [128].  These CD23+ B cells then traffic to the splenic follicles where antigen 
transfer occurs followed by rapid increases in antigen-specific CD4+ T cell proliferation 
and IgG responses [128,129].  Third, circulating IgE can bind to mCD23 on B cells and 
shut down excessive IgE synthesis [115]. 
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1.1.7 T regulatory cells and their role in allergic airway disease 
T regulatory cells (Tregs) are critical for maintaining peripheral tolerance, 
immune homeostasis, and preventing autoimmunity.  Furthermore, they are important 
for suppressing allergy and asthma as well as inducing tolerance to dietary food 
antigens and maintaining maternal tolerance to the fetus [130].  They are divided into 
two sub-populations, natural Tregs (nTregs) and inducible Tregs (iTregs) [131].  nTregs 
are derived centrally in the thymus through MHCII/TCR dependent interactions resulting 
in high-avidity selection and express a T cell receptor (TCR) that has a diverse 
repertoire for both self (although controversial) and foreign antigens [130,132].  
Because self-reactive T cells are eliminated during negative selection, it has been 
proposed that FoxP3+ T cells may resist negative selection [132].  Others believe, 
however, that while a small subset of Tregs recognize self antigen weakly, this is “the 
exception not the rule” [130].  Following differentiation in the thymus, nTregs migrate to 
the periphery to prevent autoimmune reactions by raising the threshold of activation for 
all immune responses and suppressing autoreactive T cells.  nTregs require CD28 as a 
costimulatory signal and IL-2 or IL-15 for activation [94].  iTregs, which have been more 
recently defined, are generated in the periphery in secondary lymphoid or inflamed 
tissues from CD4+FoxP3- T cells following TCR stimulation in the presence of TGFβ and 
IL-2 leading to FoxP3 expression [94].  While not described herein, there are also 2 
subclasses of FoxP3- iTregs that produce either IL-10 (Tr1 cells) or TGFβ (Th3 cells) 
[94].     
In mice, both nTreg and iTregs are defined by expression of the transcription 
factor, forkhead box 3 (FoxP3) and express the following markers: CD4+CD25+FoxP3+ 
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[94,133].  The difference is that nTregs leave the thymus already expressing FoxP3 
whereas FoxP3 expression is induced in iTregs following TCR engagement with TGFβ 
and IL-2 signaling [94].  While the exact function of FoxP3 is unknown, genome analysis 
found that it binds to about 1000 genes, some of which are important for TCR signaling, 
and therefore may act as both a transcriptional activator and repressor [130].  Other 
markers that are also characteristic of Treg cells include ICOS, PD-1, GITR, LAG3, 
CTLA-4, neuropilin-1, and Helios.  Huang et al. compared these surface markers on 
iTregs and nTregs and found that iTregs had increased ICOS and CTLA-4 compared to 
nTregs but equal levels of PD-1, GITR, LAG3, neuropilin-1 and reduced Helios [134].  A 
different report, however, states that nTregs exhibit higher expression of PD-1, 
neuropilin 1, and Helios compared with iTregs [135].  It is still difficult, therefore, to 
differentiate between these two populations in vivo as there is still controversy over their 
surface markers; and, a unique marker has not been discovered to differentiate 
between the two groups.  
Functionally, both nTregs and iTregs act synergistically to induce tolerance and 
suppress immune cell proliferation and function.  Bilate et al. proposed that the 
collaboration between nTregs and iTregs is due to their non-overlapping TCR 
repertoires [131].  Both are able to suppress (1) T cell proliferation in addition to other 
immune cell types; (2) Tbet and GATA3 upregulation, (3) cytokine production; (4) CD8+ 
T cell cytotoxic activity; and (5) antibody production [136].  Suppression mechanisms 
used include secretion of inhibitory cytokines (IL-10, TGFβ, and IL-35), competition for 
growth factors such as IL-2, and CTLA-4 mediated downregulation of T cell responses 
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[136].  However, the exact mechanisms by which nTregs and iTregs induce tolerance 
are still under investigation.  
Given that Tregs inhibit T cell proliferation, Th2 differentiation, Th2 cytokine 
production, and antibody production, it is obvious that Tregs would be beneficial in 
reducing or preventing induction of allergic diseases and asthma [136,137].  In a chronic 
OVA-induced lung inflammation model, adoptive transfer of CD4+CD25+ Tregs after 
airway disease was already established led to a reduction in eosinophils, Th2 cytokines, 
peribronchiolar lung collagen, and mucus.  Airway resistance (AHR) in this study, 
however, was not affected by Treg transfer after disease was already established [138].  
Other acute and chronic murine airway hypersensitivity studies, however, clearly 
demonstrated that Tregs reduce AHR [139–141].  Furthermore, the presence of Tregs 
appears to be protective in healthy individuals.  Healthy children or those diagnosed 
with chronic cough had increased CD4+CD25+ Tregs in BALF compared to children with 
asthma [142].  With regards to B cell IgE production, Meiler et al. demonstrated that 
Tregs exert their negative influence on allergy induction by suppressing IgE production 
and instead inducing IgG4 class-switching [143].  Furthermore, Xu et al. [141] reported 
that adoptive transfer of in vitro generated iTregs reduced OVA-specific IgE levels 
following OVA sensitization and challenge.  Overall, both nTregs and iTregs are thought 
to cooperatively limit allergic disease induction by (1) suppression of eosinophil and 
mast cell migration and activation, (2) isotype switching from IgE to IgG4, (3) 
suppression of inflammatory cell migration into lung tissue, (4) reducing AHR, and (5) 
suppressing Th2 differentiation and cytokine production (IL-4, IL-5, IL-13) [144].  
1.1.8 B regulatory cells: A unique B cell subset 
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Similar to T helper cell subsets, B cells can also be classified based on cytokines 
they produce.  A subset of B cells, termed B regulatory cells, dampen or suppress 
immune responses [145–147] .  Thomas Tedder, a pioneer in the B regulatory cell field, 
initially described B regulatory cells as IL-10 producing B cells.  However, in his recent 
review, he acknowledges that IL-10 producing B cells (B10 cells) represent a specific 
subset of B regulatory cells [148].  Mizoguchi et al. describes other mechanisms B 
regulatory cells may use, in addition to IL-10 production, to mediate immunosuppression 
including (1) TGFβ1 production, (2) IgG and IgA production to mediate neutralization of 
harmful factors, and (3) induction of apoptosis in effector T cells [147].  Non-IL10 
producing B regulatory subsets, however, are far less defined.  B10 cells, specifically, 
are known to suppress aspects of both the innate and adaptive immune response.  B10 
cells are defined functionally by intracellular IL-10 staining and unfortunately a unique 
set of surface markers has not been identified [145,146].  In mice, they are known to 
share overlapping markers with marginal zone B cells and B1 B cells including 
CD1d+CD5+IgDloIgMhi but intracellular IL-10 staining is still required for identification 
[145]. 
B10 cells develop from a B10 progenitor cell (B10pro) defined as CD1d-CD5-
MHCII+IgM+CD40+ and represent 1-2% of total splenic B cells [145,149].  The initiation 
of IL-10 secretion by B10 cells requires several factors including BCR ligation with 
antigen [150,151], CD40 ligation [152,153], and IL-21 signaling [154].  Interestingly, T 
cells are not required for B10 development but cognate interactions are important for 
eventual IL-10 secretion [154].  TLR-4 (LPS ligand) and TLR-9 (CpG oligonucleotide 
ligand) signaling augments IL-10 secretion but is not essential for B10 development 
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[151].  For instance, MyD88-/- mice have equal frequencies of B10pro and B10 cells 
compared to WT but not optimal IL-10 expression [151].  
Functionally, B10 cells suppress aspects of both innate and adaptive immunity 
through IL-10 production [155].  IL-10 can suppress proinflammatory cytokine 
production [155], MHCII and costimulatory molecule expression [156], T cell activation, 
and antigen uptake by dendritic cells [157].  Currently, there is controversy over whether 
or not B10 cells enhance Treg development and function.  Various studies using an 
experimental autoimmune encephalomyelitis (EAE) model to study multiple sclerosis 
(MS) have concluded that IL-10 made by B10 cells was both involved [158] and not 
involved [159,160] in Treg generation and function.  However, another study concluded 
that the supportive effect of B10 cells on Tregs in EAE is IL-10 independent and 
therefore another regulatory mechanism may be involved [161].  It is known, however, 
that CD19-deficient NZB/W mice, which have significantly reduced B10 cells, have 
reduced Tregs.  Furthermore, adoptive transfer of B10 cells into CD19-deficient NZB/W 
mice induced Treg expansion [162]. With regards to murine models of airway 
hypersensitivity, Amu et al. demonstrated that adoptive transfer of B10 cells induced 
nTreg recruitment into lungs, which reduced airway inflammation [163].  Overall, many 
studies have demonstrated a link between B10 cells and Treg expansion, but this 
relationship needs to be further explored.   
A central question regarding B10 function is whether B10 cells differentiate into 
plasma cells and secrete antibody.  Maseda et al. described B10 cells as transient IL-10 
producing B cells of which a subset will become antibody secreting plasma cells [164].  
Following IL-10 secretion, expression of blimp1 and irf4 transcription factors increases 
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while bcl6 decreases, which is characteristic of plasma cell differentiation.  Furthermore, 
Maseda et al. found B10 derived IgM was reactive with both self and foreign antigen; 
and, B10 cells made antigen specific IgG1 post immunization [164].  Therefore, B10 
cells are a unique B cell subset of which some retain the ability to make antibody but 
are by definition immunosuppressive in nature.       
1.1.9 Section 1 aims 
Overall, the aim of section 1 is first to define immune system characteristics of B 
cell specific ADAM10 deficient mice on two backgrounds, Th1 prone C57Bl/6 and Th2 
prone Balb/c. Specifically, the mechanisms underlying aberrant secondary tissue 
architecture and defects in antigen-specific, class-switched antibody production are 
revealed.  Furthermore, the regulation of ADAM10, ADAM17, and TNF in Th1 and Th2 
prone mouse strains and in humans is explored with an emphasis on how B cell 
ADAM10 level affects susceptibility to Th2 diseases and IgE production potential.  
Lastly, the benefit of ADAM10 inhibitor therapy and insight into its mechanism of action 
in airway inflammation models is described.    
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Chapter 2: Materials and Methods 
1.2.1 Mice 
C57Bl/6 ADAM10B−/− (CD19-cre+/-) mice (C57-ADAM10-/-) were generated as 
previously described [52] (see section 1.3.1) and backcrossed to Balb/c (Balb-
ADAM10B-/-) for 8 generations and compared to respective littermate controls (CD19-
cre-/-).  TNF knockout (TNF-αKO) mice used for bone marrow reconstitution studies 
were purchased from Jackson Laboratory (no. 005540, B6.129S-Tnf).  B6-Ly5.2/Cr 
(CD45.1) congenic mice were purchased from National Cancer Institute/National 
Institutes of Health. For B cell reconstitution studies, C57Bl/6 B cell deficient mice 
(B6.129S2-Ighmtm1cgn/J, Jackson 002288) were used.  A/J, SJL/J, C57Bl/6, and 
Balb/c WT were from Jackson Laboratories. Healthy male and female mice aged 6–12 
weeks were used in all experimentation except bone marrow reconstitution where only 
WT female mice ages 6–8 weeks were reconstituted with sex-matched bone marrow 
cells.  The Virginia Commonwealth University Institutional Animal Care and Use 
Committee approved all animal care and experimental protocols.  For experimentation, 
mice were euthanized by isoflurane inhalation and cervical dislocation.   
1.2.2 Cell Isolation 
Tissue preparation 
Single cell suspensions of spleen or peripheral lymph node was prepared by 
disrupting tissue between frosted glass slides. For peritoneal lavage, 1 mL of 2%FBS in 
PBS was injected into the peritoneal cavity and removed.  Suspensions were filtered 
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through 40-µm Nylon Mesh (Fisherbrand) and RBCs lysed with ACK Lysing Buffer 
(Quality Biological).  
Magnetic bead isolation 
Specific cell isolation was performed with magnetic bead isolation (Militenyi 
Biotec).  Briefly, a single cell suspension was generated as described above. Cells were 
washed and resuspended in MACS buffer (PBS pH 7.2, 0.5% BSA, and 2mM EDTA) 
and incubated with the corresponding magnetic beads for 20 minutes on ice. Cells were 
then washed and passed through a pre-washed magnetic column according to 
manufacturer’s protocol (Miltenyi Biotec).  For positive selection, LS columns were 
used.  Following addition of cells, columns were washed three times and then flushed 
with MACS buffer to elute cells for experimentation.  For negative selection, LS columns 
were used as described previously but flow through from column was collected.  For B 
cell isolation, total B cells were isolated using B220+ positive selection or naïve B cells 
were isolated by CD43 depletion (CD43- cells collected from flow through).   For T 
regulatory cell induction experiments, CD4+CD25- cells were isolated.  First, total 
splenocytes were incubated with CD25-PE for 10 minutes in the dark, washed, 
incubated with anti-PE beads, and CD25 negative cells collected in flow through.  
CD25- cells were then incubated with CD4 (L3T4) beads and positive selection 
performed for CD4+CD25- T cells.     
1.2.3 In vitro activation 
B cells: Anti-CD40, IL-4, LPS 
 
 
31 
B cells were grown in complete RPMI 1640 medium containing 10% heat-
inactivated (56°C, 30 min) FBS (Gemini Bio-Products, West Sacramento, CA), 2 mM L-
glutamine, 50 µg/ml penicillin, 50 µg/ml streptomycin, 1 mM sodium pyruvate, 50 µM 2-
ME, 1× nonessential amino acids, and 20 mM HEPES buffer (all from Invitrogen, 
Carlsbad, CA), and stimulated in vitro for 1, 3, or 5 d with 1000 U IL-4 (NIH) and either 
50 µg/ml LPS (from Escherichia coli 0111:B4; Sigma) or 1.25 µg/ml purified anti-mouse 
CD40 (no. 102902; Biolegend).  Supernatants were harvested at day 1, 3, or 5 for 
ELISA and cells analyzed by flow cytometry, western, and qPCR.   
B cells: PMA 
 B220+ B cells were isolated from total splenocytes and were left untreated 
(media alone) or were treated with 250ng/mL PMA (Sigma).  Cells were grown in 
complete RPMI at 37°C. Protocol adapted from [112].  
In vitro generation of CD4+CD25+ T cells 
Plates were coated with anti-CD3 (1µg/mL, Biolegend) for 2 hours at 37°C then washed 
with PBS before plating.  1mL of 2 x 106 CD4+CD25- cells (isolation described above) 
was resuspended in X-Vivo15 serum-free medium supplemented with 10% FBS 
(Gemini Bio-Products, West Sacramento, CA) (without antibiotics) and added to anti-
CD3 coated plates. Immediately, in vitro stimulating condition was added with all groups 
having anti-CD28 antibody (2 mg/mL, Biolegend) and IL-2 (100U/mL, Peprotech) in 
supplemented X-Vivo15 media [165].  Groups included media alone (negative control), 
rTGF-β1 (5 ng/mL) alone (positive control), and conditioned supernatants from 5 day 
anti-CD40/IL-4 treated B cells (WT or ADAM10B-/-) with or without ICOSL neutralizing 
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antibody (Biolegend, isotype control Rat IgG2a).  All groups were cultured for 4 days.  
Percent purity of CD4+CD25- cells was determined by flow cytometry before culture 
(>97%).  After 4 days, percent induction of FoxP3 expression in CD4+CD25+ cells was 
determined by flow cytometry or qPCR.         
1.2.4 [3H] thymidine Proliferation 
B cell and T cell proliferation was assessed after 72 h of growth, and a 24-h 
pulse of [3H]thymidine, 1 µCi/well (Perkin Elmer, Waltham, MA), was used. Plates were 
then harvested using a Filtermate cell harvester onto UniFilter-96 GF/C microplates 
(Perkin Elmer), dried overnight, and analyzed using a Topcount Plate Counter (Perkin 
Elmer).  
1.2.5 Immunization 
NP-KLH 
Mice pre-bled the day before immunization and were immunized in the footpad 
(two ipsilateral paws) and/or intraperitoneal with 10 µg 4-hydroxy-3-nitrophenylacetyl 
coupled to keyhole limpet hemocyanin at a ratio of 27:1 (NP27KLH or NP-KLH herein) 
(Biosearch Technologies) in 4 mg alum. For footpad injections, mice were given 10µg 
NP-KLH (1µg/mL stock) in 9µL of PBS and 15µL of alum for a total of 25µL per paw.  
For intraperitoneal injections, mice were given 10µg of NP-KLH (1µg/mL stock) in 90µL 
of PBS and 100µL of alum (4 mg) for a total of 200 µL per injection.  Mice were bled at 
day 7, 14, and/or 21 post immunization and serum used for ELISA.   
1.2.6 ELISA 
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Total antibody  
ELISA plates were coated with 5µg/mL of goat-anti Ig (SouthernBiotech) in BBS 
(0.15M sodium chloride, 0.01 M borate buffer, pH=8.5) and incubated at 37°C for an 
hour or at 4°C overnight. Plates were then washed three times with ELISA wash (PBS 
with 0.02% Tween20). Blocking solution (PBS with 0.02% Tween20 and 2% FBS) was 
then added and incubated at 37°C for an hour or at 4°C overnight. Plates were then 
washed three times with ELISA wash and samples were added, diluted in block.  For 
standard curve, normal mouse Ig (Southern Biotech) was used and incubated at 37°C 
for an hour. Plates were washed three times with ELISA wash and incubated with goat-
anti Ig-AP diluted 1:400 in block (Southern Biotech) for 1 hour at 37°C. Plates were 
washed five times and developed with phosphate tablets (Sigma-Aldrich) dissolved in 
substrate buffer (0.1g MgCl2.6H20, 0.2 NaN3, 50mL diethanolamine, pH to 9.8 per 
500mL). Absorbance at 405nm was measured. 
NP-specific antibody  
ELISA plates were coated with 15µg/mL NP4BSA (high affinity) or NP25BSA (low 
affinity) in PBS for sample wells and with 5 µg/mL of goat-anti-Ig (Southern Biotech) in 
BBS for standards.  The remaining steps were carried out as described above in ‘total 
antibody’ section.  
TNF 
Soluble TNF from B cell supernatants was determined by mouse quantitative 
ELISA kit (88-7324-88; eBioscience) according to manufacturers’ protocol. 
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HDM specific IgE 
HDM specific IgE ELISA was performed as described [31,166]. Briefly, plates 
were coated with 20µg/mL HDM extract in 50mM carbonate buffer, blocked with 
SuperBlock (Thermo Scientific), detected using goat anti-mouse IgE (Abcam), followed 
by addition of Streptavidin-HRP (Southern Biotechnologies), and color developed with 
tetramethylbenzidine + substrate (BD Biosciences).  Reaction was stopped with 1N 
H2SO4 and absorbance read at 450nm. 
MUC5AC 
BALF supernatants were analyzed for MUC5AC protein by ELISA as described 
[167].  Briefly, BALF was diluted and 75µL was incubated with 75µL carbonate buffer.  
Samples were incubated overnight without a lid at 37°C then washed three times with 
PBS.  Plates were blocked, detected with anti-Muc5AC mouse monoclonal antibody 
(Pierce, 1:100), followed by addition of goat anti-mouse IgG-HRP (Southern 
Biotechnologies,1:10,000), developed with tetramethylbenzidine + substrate (BD 
Biosciences), stopped with 1N H2SO4, and absorbance read at 450nm.  
1.2.7 PCR and Quantitative PCR  
PCR 
For genotyping, DNA was isolated using Direct Tail PCR Solution as directed by 
the manufacturer (Viagen). Mangomix (Bioline) was used for amplification of CD19 cre-
lines, ADAM-10 floxed alleles, YFP-Rosa and ADAM17. Cycling conditions were as 
follows, 95°C for 3 minutes then 35 cycles of 94°C for 1 minute, 55°C for 1 minute, 72°C 
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for 2 minutes, and a final extension at 72°C for 10 minutes. Sequences of all primers 
described above are listed in Table 1. 
Quantitative PCR 
Total RNA was extracted from naive and stimulated total B cells using TRIzol 
reagent (Invitrogen) according to manufacturer’s protocol and RNA concentration 
quantified by a ND-100 NanoDrop spectrophotometer. RNA (400 ng/µl) was reverse 
transcribed using an iScript cDNA Synthesis Kit (Bio-Rad). Real-time quantitative PCR 
(qPCR) was performed with a real-time PCR machine (iQ5; Bio-Rad Laboratories). 
Primers and probes used for TaqMan qPCR assay (all from Applied Biosystems) are 
listed in Table 1. Fold variation was determined using the ∆∆Ct method of analysis 
[168]. 
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Table 1: PCR and qPCR primers and probes 
PCR 5’>3’ 
A10Flox (75302-75324) Exon 9 GTTGGACATAACTTTGGATCTCC 
A10Flox (75536-75516) Intron 9 CGTATCTCAAAACTACCCTCC 
A10Flox  (74490-74513) Intron 8 TGTGTGAATAGTGCAGTGAACGCC 
A17Flox F TCCCCCAGCTAGATTGTTTG 
A17Flox R AGGACCCAGGTTCAGTTCCT 
CD19 sense TCGCGATTATCTTCTATATCTTCAG 
CD19 antisense GCTCGACCAGTTTAGTTACCC 
YFP1 (oMIR 316) GGAGCGGGAGAAATGGATATG 
YFP2 (oMIR 833) AAAGTCGCTCTGAGTTGTTAT 
YFP3 (Ro 4982) AAGACCGCGAAGAGTTTGTC 
TNF F1 TACACAGAAGTTCCCAAATG 
TNF F2 TCCCTCTCATCAGTTCTATG  
TNF R1 GAAATCTTACCTACGACGTG  
TNF R2 AAGCATCTATGCACTTAGAC 
PCR: For detecting CRE-mediated deletion of the STOP cassette at the 
ROSA/EYFP locus 
 
ROSA26 (3937-3958) TGGAGGCAGGAAGCACTTGCTC  
EYFP (29-8) GTGAACAGCTCCTCGCCCTTGC 
Quantitative PCR All from Applied Biosystems 
18s Mm03928990 
ADAM10 Mm00545742 
ADAM17 Mm00456428 
FoxP3 Mm00475162 
GAPDH Mm99999915 
Matrix metalloproteinase 13 (MMP13) Mm00439491 
TNF-α Mm00443258 
TTP/Zfp36 Mm00457144 
Human adam10 Hs00153853 
Human adam17 Hs01041915 
Human TNF Hs01113624 
Human GAPDH Hs02758991 
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1.2.8 Western 
Protein lysates were made according to the manufacturer’s protocol using Cell 
Lysis Buffer (no.9803; Cell Signaling). Equal amounts of protein determined by Bradford 
Assay were loaded onto Novex NuPAGE 10% Bis-Tris gels (Invitrogen), run for 35 min 
at 200 V at RT, transferred to nitrocellulose membrane at 90 V for 2 hours on ice, and 
equal transfer verified by Ponceau S (Sigma) staining.  Blots were blocked (PBS, 0.02% 
Tween-20, 5% dry milk) for 1 hour at RT or overnight at 4°C.  Blots were then washed 3 
times for 10 minutes (PBS, 0.02% Tween-20).  Primary antibodies listed in Table 2 
were diluted in block and incubated overnight.  Blots were again washed 3 times and 
incubated with respective secondary antibodies or anti–β-actin peroxidase (Table 2) for 
2 hours at RT.  Plates were washed 3 times and signal detected with 1:1 mix of 
SuperSignal West Pico Chemiluminescent Substrate (no. 34080; Thermo Scientific).  
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Table 2: Western Antibodies 
Name Source Catalog Number Dilution 
anti–β-actin peroxidase Sigma A3854 1:25,000 
anti-ADAM17 Abcam 2051 1:1,000 
Goat anti-rabbit IgG, 
HRP conjugate 
secondary 
Southern 
Biotechnologies 
4030-05 1:5,000 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
39 
1.2.9 Flow cytometry and immunohistochemistry 
For all flow staining procedures, cells were isolated as in 1.2.2.  
Flow cytometry – Surface, total (intracellular and extracellular), and nuclear staining 
0.5-3 x 106 cells were washed in FACS buffer (2% FBS in PBS), decanted, and 
incubated on ice with 1-5µg of Fc block (2.4G2) for 10 minutes to prevent non-specific 
staining. Subsequently, cells were surface stained by incubating 0.25-0.5µg of anti-
mouse antibodies (Table 3) for 30 minutes on ice. Cells were then washed with FACS 
buffer.  If further performing total staining, cells were fixed (FCM Fixation Buffer, Santa 
Cruz Biotechnology) at RT for ten minutes, washed, permeabilized for 10 minutes at 
RT, washed, Fc-blocked for 10 minutes on ice, and stained for 30 minutes on ice with 
anti-mouse or anti-human antibodies.  For secondary staining, cells were washed with 
FACS buffer after primary staining and then stained with secondary antibodies (Table 
3).  If performing nuclear staining, cells were fixed (Biolegend Nuclear Fixation Buffer) 
for 20 minutes at RT, washed, permeabilized (Biolegend Nuclear Permeabilization 
Buffer), Fc Blocked, and stained.     
Flow cytometry - Tyramide Signal Amplification  
0.5-3 x 106 cells were stained using tyramide signal amplification (TSA) Kit #26 
with HRP streptavidin (no. T20936; Molecular Probes) and an anti-mouse B220 
antibody (Table 3). Kit reagents were prepared according to manufacturer’s protocol, 
and tyramide amplification using the “Peroxidase Labeling assay” was performed with 
the following modifications: cells were incubated with blocking reagent (10 µg anti-
mouse unlabeled CD16/32 [2.4G2]) for 15 min; stained with biotin anti-mouse TNF-α 
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primary Ab (Biolegend); and after tyramide labeling, cells were washed twice and 
stained with anti-mouse B220 (see earlier) for 30 minutes.  
Flow cytometry – ICOSL cleavage kinetics 
B220+ B cells were stained at time 0 for baseline ICOSL expression following Fc 
blocking with 10µg anti-mouse unlabeled CD16/32 [2.4G2] for 15 minutes.  B cells 
treated with PMA were cultured for 5, 10, 20, 30, 45, 60, or 120 minutes at 37°C.  At 
each time point, cells were blocked and then stained for biotin anti-mouse ICOSL 
followed by PE-Strepavidin.     
Flow Analysis 
For analysis, all samples were washed and resuspended in 500µL PBS. Flow 
cytometry analysis was performed using a Canto or Fortessa (BD Biosciences) using 
DIVA software at the Flow Cytometry Core at Virginia Commonwealth University. Data 
analysis was performed with FCS Express, v. 4. 
Immunohistochemistry 
Ten-micrometer-thick frozen sections were cut from the excised mouse LNs, 
fixed in absolute acetone, air-dried, and blocked with serum-free protein block (X0909; 
Dako). The sections were dual- and triple-labeled for FDCs (CD21/CD35), B cells 
(CD45R/B220), high endothelial venules (HEVs; anti-mouse/human peripheral node 
addressin), T cells (rat anti-mouse CD90.2/Thy-1.2-PE), collagen type 1, and TNF-α 
(Table 3). Sections were mounted with antifade mounting medium, Vectashield (Vector 
Laboratories), coverslipped, and examined with a Leica TCS-SP2 AOBS confocal laser-
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scanning microscope. Three lasers were used: argon (488 nm), HeNe (543 nm), and 
HeNe (633 nm; far red emission is shown as pseudoblue). Parameters were adjusted to 
scan at 1024 × 1024 pixel density and 8-bit pixel depth. Emissions were recorded in two 
or three separate channels, and digital images were captured and processed with Leica 
Confocal, LCS Lite software, and ImageJ for color separation and quantitative 
assessment of immunohistochemistry. 
Immunohistochemistry – Tyramide Signal Amplification 
TNF labeling was enhanced using fluorescein-TSA (TSA Plus Fluorescein 
System; NEL741001KT; Perkin Elmer). In brief, after quenching endogenous 
peroxidase using 1% H2O2, anti–TNF-α Ig was applied for 2 h, washed, then HRP-
conjugated secondary Ig was added for 1 h. After washing, HRP was allowed to 
catalyze the deposition of fluorescein-labeled tyramide for 10 min, then was washed, 
mounted, and examined. 
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Table 3. Flow Cytometry and Immunohistochemistry Antibodies 
*All antibodies are anti-mouse unless otherwise specified.   
 
 
 
 
Name Label Source Concentration 
used 
Flow Cytometry               
ADAM10 PE R&D N/A 
Anti-human ADAM10 FITC R&D  
Anti- mouse and human 
ADAM17 
Unconjugated Abcam N/A 
B220/CD45R  APC, FITC, PE Biolegend N/A 
CD4 PECy7 Biolegend N/A 
CD25 PE Biolegend N/A 
FoxP3 Alexa 647 Biolegend N/A 
TNF Biotin Biolegend N/A 
DyLight-649 anti-rabbit 
IgG (secondary for 
ADAM17) 
APC Biolegend N/A 
Mouse IgG2b  FITC R&D N/A 
Rat IgG2a PE Biolegend N/A 
Rabbit IgG Unconjugated In house N/A 
ICOSL Biotin Biolegend N/A 
Streptavidin PE Biolegend N/A 
IL-10 APC Biolegend N/A 
Anti-human CD19 PE Biolegend N/A 
Anti-human CD14 APC Biolegend N/A 
Anti-human CD3 PE Biolegend  N/A 
Immunohistochemistry    
CD21/CD35 PE Biolegend 5-10 µg/mL 
CD45R/B220 Alexa Fluor 647 Biolegend 5-10 µg/mL 
CD90.2/Thy-1.2 PE Southern 
Biotechnologies 
5-10 µg/mL 
Collagen Type 1 Unconjugated Abcam 5-10 µg/mL 
Peripheral node 
addressin (anti-
mouse/human) 
Unconjugated Biolegend 5-10 µg/mL 
TNF TSA Abcam 5-10 µg/mL 
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1.2.10 Bone marrow reconstitution 
Bone marrow cells were isolated as previously described with the following 
modifications [169]. In brief, two femurs and two tibias from each mouse (WT [CD45.2], 
ADAM10B−/−[CD45.2], or TNF-αKO) were centrifuged, RBCs lysed with ACK Lysing 
Buffer (Quality Biological), bone marrow cells counted, and 5 million cells were i.v. 
injected. For 50/50 mixtures, such as ADAM10B−/− + TNFKO, 100 µl/2.5 million cells 
from each were used to prepare the final injection mixture. 
B6-Ly5.2/Cr (CD45.1) congenic mice from National Cancer Institute/National 
Institutes of Health were pretreated 5 days before irradiation with 100mg/L 
(concentration 0.01%) enrofloxacin (Baytril) in sterile water. CD45.1 mice were 
anesthetized using a 100 µL i.p. injection of ketamine/xylazine in PBS at a dose of 80 
and 8 mg/kg, respectively. This was followed by two doses of 550 cGy irradiation, 
separated by a 2-hour rest period, using an MDS Nordion Gammacell 40 research 
irradiator with a [137Cs] source. After irradiation, mice were reconstituted by i.v. injection 
with the indicated bone marrow cells as described earlier. After 6 weeks of 
reconstitution, mice were footpad immunized in two ipsilateral paws with 10 µg 4-
hydroxy-3-nitrophenylacetyl coupled to keyhole limpet hemocyanin at a ratio of 27:1 
(Biosearch Technologies) in 4 mg alum. Draining and non-draining popliteal and axillary 
LNs were dissected at 14 days post-immunization and analyzed by 
immunohistochemistry. 
1.2.11 Human Studies 
The Virginia Commonwealth University IRB approved all human studies.  Sixteen 
symptomatic allergic rhinitis patients and 16 controls were recruited for the study by Dr. 
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Anne-Marie Irani at VCU. Inclusion criteria included active allergic rhinitis symptoms and 
a documented positive skin test or ImmunoCAP to an antigen as consented in IRB 
#00870.  Peripheral blood mononuclear cells (PBMC) were isolated from peripheral 
blood using Ficoll, stained, and remaining PBMC underwent CD19 B cell selection using 
magnetic beads (Miltenyi Biotec). B cells were cultured for 2 days (or 5 days for CD23 
ELISA) with 200 ng/mL human IL-21 (ATCC), 1 µg/mL anti-CD40 (Clone G28-5, ATCC), 
and 10 ng/mL rhIL-4 (R&D). Stimulated B cells were harvested, stained for flow 
cytometry, analyzed by qPCR, and sCD23 determined by ELISA [170].. HDM 
Dermatophagoides pteronyssinus IgE was determined by ImmunoCAP (Phadia, 14-
4107-01). 
1.2.12 Murine HDM Studies 
C57Bl/6 WT, C57-ADAM10B-/-, Balb/c WT, and Balb-ADAM10B-/- mice were 
intranasally exposed to 25µL saline or 15µg/25µL HDM extract (Greer Laboratories) as 
described in Figure 18 [171].  For Treg depletion studies, 0.5mg/mL anti-CD25 
(BioXCell, PC-61.5.3), 0.5mg/mL COH2 (control rat IgG1), or PBS was given i.p. 3 days 
before first intranasal immunization and again 3 days after the first intranasal 
immunization.  Bronchoconstriction was assessed using Flexivent (Scireq, Montreal, 
QC, Canada) as previously described [167]. Airway resistance (Rrs or AHR) was 
determined at increasing doses of methacholine (5, 10, 25 mg/ml) and presented as (1) 
percent increase from PBS baseline or (2) resistance value for each dose shown. 
Total BALF volume and cell count was assessed and total cell count normalized 
to 100µL.  BALF supernatants were analyzed for MUC5AC protein by ELISA as 
described [167] (see Section 1.2.6).   
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1.2.13 Murine Lung Histology 
Five µm sections of formalin-fixed, paraffin-embedded murine lung tissue were 
stained with hematoxylin and eosin (H&E) and Periodic acid-Schiff (PAS) (AML 
Laboratories, Inc. Baltimore, MD) and photographed using Olympus-DP70 camera on 
Olympus-BX41 microscope.  Histopathologic evaluation of H&E stained lung sections 
from at least 4 mice per group was performed by a pathologist in a blinded fashion 
using a semi-quantitative scoring system on a Nikon Eclipse microscope.  
Peribronchiolar and perivascular inflammatory cellular infiltration were scored separately 
as follows: 0, no or occasional cells; 1, few or loosely arranged cells; 2, focal 
involvement of lung parenchyma with majority of airways or vessels having rings (partial 
or complete) of inflammatory cells one cell layer deep; 3, patchy involvement of lung 
parenchyma with majority of airways or vessels having rings (partial or complete) of 
inflammatory cells two to four cell layers deep; 4, extensive involvement of lung 
parenchyma with majority of airways or vessels having rings (partial or complete) of 
inflammatory cells more than four cell layers deep. Individual scores for peribronchiolar 
and perivascular inflammation were added together for a total maximum score of 8.    
1.2.14 BALF by flow cytometry 
 BALF cells were stained with APC-B220, APC-CD3, BV421-1A/1E, BV605-CD11c, and 
PE-CCR3 (Biolegend) after FcR blockade with anti-mouse CD16/32 (2.4G2). Samples 
were examined on a BD Fortessa and analyzed with FCS Express, v. 4. using the 
gating strategy described [172]. 
1.2.15 Statistical Analysis 
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Normal distribution of data sets was determined using the Shapiro-Wilk normality 
test with SigmaPlot 12.5.  Furthermore, the mean and medians were close for data sets 
indicative of normal distribution.  When dealing with two groups, p-values were 
calculated using unpaired two-tailed Student’s t-tests in GraphPad Prism. In the case of 
non-parametric populations, p-values were calculated using two-tailed Mann-Whitney 
test. When more than two were compared, p-values were calculated using a one-way 
analysis of variance (ANOVA) with a Tukey post-test.  Error bars represent the standard 
error of the mean (SEM), standard deviation, or 95% confidence interval between 
samples. p<0.05 is considered significant. 
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Chapter 3:  Th1 vs. Th2 background does not affect antigen specific antibody 
production following B cell ADAM10 deletion; however, Th context greatly affects 
B cell ADAM17 and TNF regulation and thus secondary lymphoid tissue 
architecture 
1.3.1 Generation of B cell specific ADAM10 deficient mice on two backgrounds 
 Our lab previously generated a B cell specific ADAM10 deficient mouse model 
(ADAM10B-/-) on both a C57Bl/6 and Balb/c background.  C57Bl/6 ADAM10B-/- (C57- 
ADAM10B-/-) mice were initially generated by crossing homozygous floxed ADAM10 
(exon 9) mice with CD19-cre knockin mice [52].  Exon 9 in the ADAM10 gene encodes 
the zinc binding domain of the protease active site and cre-mediated deletion causes a 
frameshift mutation, which disrupts transcription.  CD19 is expressed starting at the pro-
B cell stage, but CD19-cre recombination is limited to the immature B cell or pre-B cell 
[173]. To confirm B cell specific ADAM10 deletion, PCR analysis for exon 9 was 
performed on B220+ B cells and B220- splenocytes [52].  C57- ADAM10B-/- mice were 
then crossed with YFP reporter mice, which have a floxed stop codon upstream of a 
YFP reporter gene.  Successful recombination defined by YFP expression using flow 
cytometry analysis indicated 87% of splenic B cells and 95% of peripheral lymph node B 
cells in C57-ADAM10B-/- were YFP positive [52].  Therefore, this mouse only expresses 
YFP after cre-mediated recombination in B cells as outlined in Figure 2.  Balb/c 
ADAM10B-/- (Balb-ADAM10B-/-) mice were generated by crossing C57-ADAM10B-/- to 
Balb/c WT (Jackson) for 8 generations.  
 
 
  
Figure 2. B cell specific ADAM10 deficient mouse model.
Cre-recombinase (cre) is under the control of the CD19 promoter
allele.  CD19 expression occurs in B cells leading to cre expression.  Note, that this 
allele is kept heterozygous with one WT CD19 allele to avoid disruption in CD19 
expression.  Cre cleaves at loxP sites that flank exon 9 of both ADAM10 alle
renders ADAM10 ineffective.  Additionally, these mice express a YFP reporter gene to 
track successful ADAM10 deletion.  Cre cleaves at loxP sites flanking a STOP 
sequence upstream of the YFP
the YFP-Rosa gene is transcribed and expressed on ADAM10 deficient B cells. (A) WT 
genotype. Cre negative mice exhibit WT ADAM10 expression and no YFP expression.  
(B) B cell ADAM10 deficient genotype. Cre positive mice express cre when CD19 is 
transcribed.  Cre deletes ADAM10 and the STOP sequence, thus YFP is expressed. 
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 (P) on one CD19 
-Rosa gene.  With the excision of the STOP sequence, 
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1.3.2 Humoral immune responses in C57-ADAM10B-/- deficient mice 
 Figures 3-6 are presented as background work performed by Dr. Joanna Cichy 
and Dr. Natalia Chaimowitz prior to my project.     
ADAM10 is highly expressed on GC B cells 
 Because ADAM10 cleaves many substrates potentially involved in B cell humoral 
responses including Notch 1, Notch 2, TNF, and CD23 [1,174,175], our lab in 
collaboration with Joanna Cichy from Jagiellonian University, Krakow, Poland 
investigated the expression of ADAM10 on GC B cells.  Peyer’s patches (PPs) are a 
secondary lymphoid tissue located in the intestine and exhibit a high level of GC activity.  
Flow cytometric analysis of WT PPs demonstrated that 2% of naïve B cells express 
ADAM10 while 80% of GC B cells are ADAM10+ (Figure 3A, B). Increased ADAM10 
expression on GC B cells was confirmed by immunoflourescent staining of sectioned 
PPs (Figure 3C).  Taken together, ADAM10 is expressed highly in GC B cells.     
Reduced total and antigen specific humoral responses in C57-ADAM10B-/- mice 
 Given that ADAM10 is expressed highly on GC B cells, both total and antigen 
specific antibody responses were next examined.  Basal levels of total IgM, IgG1, 
IgG2a, and IgG2b from naïve mice were reduced in C57-ADAM10B-/-, suggesting a 
defect in antibody production (Figure 4A).  Next, mice were immunized i.p. with NP-
KLH (NP) in alum and antigen specific antibody production was assessed.  NP-specific 
IgM was reduced in C57-ADAM10B-/- mice 7 days post immunization, but reached WT 
levels by day 14 and remained comparable at day 21 and 28 (Figure 4B).  Both total 
and high affinity NP-specific IgG were significantly reduced C57-ADAM10B-/- mice at day 
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7, 14, 21, and 28 post immunization (Figure 4B).  When boosted with NP-KLH at day 
42 post immunization, total and high affinity IgG antibody titers still failed to recover to 
WT levels (Figure 4C).  NP-specific IgG1, IgG2a, and IgG2b were assessed at day 28 
and were reduced in C57-ADAM10B-/- compared to WT (Figure 5A).  Furthermore, 
immunization with 1mg of NP-KLH in alum still revealed reduced NP-specific IgG 
responses in C57-ADAM10B-/- demonstrating that increased antigen dose cannot 
overcome the antibody defect (Figure 5B).    
 
 
 
 
 
 
 
Figure 3.  ADAM10 expression on GC 
(A and B) Expression of ADAM10 on gated GC PNA
(red) B cells (CD19+) isolated from PPs. Flow cytometry gates used to define the GC 
and naive B cell populations are indicated on the left. To demonstrate specificit
staining, we used isotype-matched monoclonal antibody (mAb). (A) Gating protocol is 
shown. (B) Percentage of ADAM10
sections of PPs were stained to detect B cell follicles (B220
and ADAM10 (red) (right panel) or isotype matched mAb (left panel).  Original 
magnification 20x. The mucosal epithelium (E) (left panel) also reacts with PNA and 
anti-ADAM10.  Figure courtesy of Joanna Cichy, from Jagiellonian University, Krakow, 
Poland. 
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B cells. 
hiIgDlo (blue) and naive PNA
+ cells in naive and GC B cells. (C) Frozen serial 
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Figure 4.  C57-ADAM10B−/− mice have impaired humoral responses
(A) Serum total IgM, IgG1, IgG2a, and IgG2b were measured by ELISA from naive 8
12-wk-old mice. (B) ADAM10
10µg NP-KLH emulsified in alum. At the indicated times, serum samples were collected 
and total NP-specific IgM, total IgG, and high
determined by ELISA, with NP
capture Ag for high-affinity ELISA. (C) Mice were immunized with NP
alum, rested for 42 d, and boosted with 10 
throughout the course of the experiment. Total 
were measured by ELISA at each time point. The relative unit (RU) values for alum
injected mice were <0.001.  WT (white bars) and ADAM10
represent the mean ± SEM of five to nine mice per 
0.001). Data represent results obtained in at least two independent experiments.
courtesy of Dr. Natalia Chaimowitz.  
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Figure 5.  Decreased NP-specific IgG secretion is not IgG subset dependent and 
cannot be overcome by high antigen dose. 
(A) ADAM10B-/- mice and WT controls were immunized with 10µg NP-KLH emulsified in 
alum. Twenty-eight days after primary immunization, samples were collected and NP-
specific IgG1, IgG2a and IgG2b antibody titers were determined by ELISA with 
NP14BSA as capture antigen. (B) ADAM10
B-/- and WT controls were immunized i.p. with 
1mg of NP-KLH emulsified in alum.  Samples were collected at the indicated time post 
immunization, and NP-specific antibodies were measured.  The relative unit (RU) values 
for alum-injected mice were <0.001.  WT (white bars) and ADAM10B-/- (black bars).  
Bars represent the mean ± SEM of 5 mice per group.  Data represents results obtained 
in two independent experiments. (*p<0.05, **p<0.01, ***p<0.001).  Figure courtesy of 
Dr. Natalia Chaimowitz.   
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1.3.3 Aberrant secondary lymphoid tissue architecture, TNF, and ADAM17 in C57-
ADAM10B-/- mice 
Reduced GC B cells in C57-ADAM10B-/- spleen 
 Figures 4 and 5 demonstrated that C57-ADAM10B-/- mice exhibit impaired 
antibody production and most impressively impaired class-switched antibody 
production.  Because class switching occurs in germinal centers, we next enumerated 
GC B cells (IgMloIgDloB220+IgG1+CD38lo) by flow cytometry (Figure 6A).  Following 14 
or 21 days post NP-KLH/alum immunization, splenic GC B cells were reduced by both 
percentage (Figure 6B) and total number (Figure 6C) in C57-ADAM10B-/- mice 
compared to WT.   
C57-ADAM10B-/- mice exhibit abnormal lymph node architecture and excessive TNF in B 
cell regions 
In addition to reduced GC B cell numbers, Chaimowitz et al. described secondary 
lymphoid tissue architecture defects in immunized LNs isolated from C57-ADAM10B-/- 
mice, which supported the reduced antibody production noted in these mice [107].  
These defects included improper localization of B and T cells, reduced germinal center 
formation, and a decrease in follicular dendritic cell (FDC) networks [107].  These 
architecture aberrancies bore some similarity with secondary lymphoid tissue defects 
noted in early studies of global TNF deficient mice.  Specifically, lack of splenic B cell 
follicles, disorganized FDC networks, and aberrant germinal centers [32].  Recent 
studies using B cells only capable of expressing mTNF showed that sTNF produced by 
B cells is required for maintaining secondary architecture and for IgG production against 
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T dependent antigens [34].  Taken together, B cell ADAM10 and TNF are both critical in 
maintaining proper secondary lymphoid architecture and class switched antibody 
production, but a link between them is still unclear.   
Figure 7 shows immunohistochemistry analysis of lymph nodes from naïve (non-
immunized) WT and C57-ADAM10B-/- mice.  While initial studies had indicated a 
relatively normal architecture in C57-ADAM10B-/- nodes in the absence of immunization 
[107], additional analysis revealed that not only are lymph node FDC networks largely 
absent and B/T boundaries intermingled (Figure 7A, 7B), but other abnormalities can 
also be seen.  These changes include excessive collagen deposition as well as an 
increase in high endothelial venules (HEVs), especially within B cell cortical regions 
(Figure 7B, C).  Most striking, however, was the dramatic increase in TNF within the B 
cell regions of C57-ADAM10B-/- nodes (Figure 7D).  Given the data in Figure 7 and 
previous reports of secondary lymphoid tissue architecture abnormalities in TNF 
knockouts and those only capable of expressing mTNF, it appears that not only 
subnormal but also excessive TNF levels in the lymph node cortices may lead to 
disruption of normal follicular architecture.  
B cells from C57-ADAM10B-/- mice exhibit increased expression, stability and production 
of TNF 
Given the excessive TNF staining in B cell regions of C57-ADAM10B-/- lymph 
nodes (Figure 7), we further analyzed differences in TNF expression and production in 
B cells purified from both C57-ADAM10B-/- and WT mice.  As can be seen in Figures 8A 
and 8B, flow analysis for mTNF revealed that both naïve and stimulated C57-ADAM10B-
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/- B cells exhibit increased mTNF.  Furthermore, ELISA analysis of supernatants from 
C57-ADAM10B-/- B cells cultured with LPS/IL-4 (Figure 8C) or anti-CD40/IL-4 (Figure 
8D) for 1, 3, or 5 days all showed significantly higher sTNF production compared to WT.   
 Relative (Figure 9A) and absolute (Figure 9B) TNF message analysis by qPCR 
indicated a strong increase in TNF message in C57-ADAM10B-/- compared to WT B 
cells post stimulation in vitro.  Furthermore, Tristetraprolin (TTP), which promotes TNF 
mRNA degradation [176,177], was reduced 2 fold in C57-ADAM10B-/- B cells (Figure 
9C), which have increased sTNF and mTNF (Figure 8) compared WT B cells.  The 
combined results of increased TNF message as well as membrane and soluble protein, 
suggests a possible feedback mechanism in which increased TNF shedding 
upregulates further TNF production.  In any case, it is clear that TNF is increased at 
both the message and protein level in C57-ADAM10B-/- B cells. 
C57-ADAM10B-/- B cells exhibit higher ADAM17 gene and protein expression 
ADAM17 is known to be the principle sheddase of membrane bound, pro-TNF.  
Since, C57-ADAM10B-/- B cells exhibit higher expression and production of TNF, we next 
examined ADAM17 expression and function by analyzing ADAM17 message (Figure 
10A, 10B) and protein levels (Figure 10C, 10D) in WT compared to C57-ADAM10B-/- B 
cells.  While both naïve and stimulated C57-ADAM10B-/- B cells express significantly 
more ADAM17 message (Figure 10A, 10B), relative gene expression analysis showed 
that in the naïve state, C57-ADAM10B-/- B cells express 2 times higher ADAM17 
compared to WT, which increased to 5 fold higher expression upon stimulation (Figure 
10A).  Similarly, absolute RNA quantification revealed that naïve C57-ADAM10B-/- B 
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cells exhibit significantly increased ADAM17 mRNA expression, which increases further 
upon stimulation (Figure 10B).  Western blot analysis, furthermore, showed a 2.3 fold 
increase in ADAM17 protein levels in naïve C57-ADAM10B-/- B cells over WT, which too 
increased upon stimulation to 5 fold (Figure 10C, 10D).  Upon overexposure of the 
blots, both the precursor and glycosylated forms of ADAM17 were seen (data not 
shown).   
In addition, Vandenbroucke et al. recently established that matrix 
metalloproteinase MMP13 also cleaves TNF at least in intestinal epithelium [178].  
qPCR analysis of MMP13 in naïve B cells, however, showed there was no difference 
between WT and C57-ADAM10B-/- B cells (∆∆Ct = 1.04; fold change ADAM10B-/- over 
WT).  Western blot, furthermore, failed to show MMP13 protein in naïve WT and 
ADAM10B-/- B cells compared to positive control, RAW 264.7 macrophages (data not 
shown).  This finding is in agreement with the report that significant levels of MMP13 are 
not found in B cells [179].  Taken together, Figures 6-10 demonstrate that ADAM10 
deletion from C57Bl/6 B cells results in a compensatory increase in ADAM17 
expression and activity leading to excessive TNF cleavage.  The aberrant signaling 
environment created by this compensatory effect is an excellent candidate to explain 
the abnormal lymphoid tissue architecture in our C57-ADAM10B-/- model and was thus 
further explored. 
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Figure 6.  GC formation after T-dependent immunization. 
 
ADAM10B−/− and WT mice were immunized with 10µg NP-KLH emulsified in alum. 
Fourteen and 21 days post-immunization, flow cytometry was carried out and the 
presence of GC B cells (IgMloIgDloB220+IgG1+CD38−) in the spleen of WT and 
ADAM10B−/− mice was assessed. Staining protocol is depicted (A). Both percentage (B) 
and total number (C) of GCs were enumerated. WT (white bars) and ADAM10B-/- (black 
bars). Bars represent the mean ± SEM of eight mice per group. *p < 0.05, **p < 0.01. 
Data is representative of three independent experiments.  Figure courtesy of Dr. Natalia 
Chaimowitz.   
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Figure 7.  Naïve C57-ADAM10B-/- lymph nodes (LNs) display abnormal follicular 
architecture.    
Compared to WT, ADAM10B-/- mice (A) lack well developed FDC reticula (red, CR1/2) in 
the B cell follicle (blue, B220), (B) lack B cell/T cell (red, CD3) segregation with more 
HEVs (green, pNAD) in the LN cortex, (C) display more collagen (green) deposition in 
the B cell follicle, and (D) express higher levels of TNFα than WT mice. Scale bar = 50 
mm, and micrographs are representatives of at least 3 LNs. 
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Figure 8. Increased TNF surface expression and production in C57-ADAM10B-/- B 
cells. 
Naïve (A) and 5 day stimulated (B) (LPS + IL-4) WT (black thin line) and ADAM10B-/- 
(black bold line, A10KO) live B cells were analyzed for co-expression of TNF using 
tyramide signal amplification.  Black bars (overlay plots) indicate B cells staining high in 
mTNF, represented in bar graphs (A,B). N=9 per group, 3 independent studies.  (C,D) 
Supernatants were harvested on day 1, 3, or 5 from WT (white) or ADAM10B-/- (A10KO, 
black) B cell cultures stimulated with LPS + IL-4 (C) or anti-CD40 + IL-4 (D) and sTNF 
determined by ELISA. N=9 per group, 3 independent studies. *indicates p<0.05, ** 
indicates p<0.005. 
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Figure 9.  Increased TNF gene expression and message stability in C57-
ADAM10B-/- B cells. 
Naïve (3A [checkered], 3B [left], 3C [checkered]) or 5 day stimulated (LPS + IL-4) (3A 
[stripe], 3B [right], 3C [stripe]) B cells were analyzed by qPCR for TNFα (A, B) and TTP 
(C) message normalized to 18s.  Data presented as fold change of ADAM10B-/- over WT 
(A) or fold change of WT over ADAM10B-/- (C) using the (∆∆)Ct method of analysis. 
Absolute RNA quantification for TNFα normalized to 18s in WT (white) and ADAM10B-/- 
(black) B cells appears in (B).  N=9 per group, 3 independent studies. *indicates p<0.05, 
***indicates p<0.0005. 
 
 
 
 
 
 
Figure 10. Increased ADAM17 message and protein levels in 
cells.  
Naïve (4A [checkered], 4B [left], 4C) or 5 day stimulated (4A [stripe], 4B [right], 4D) 
(LPS + IL-4) B cells were analyzed by qPCR and western blotting. (A) Relative ADAM17 
expression normalized to 18s presented as fold change of ADAM1
WT using the (∆∆)Ct method of analysis. (B) Absolute quantification of ADAM17 RNA 
normalized to 18s. N=9 mice per group, 3 independent studies. Band densitometry of 
naïve (C) and stimulated (D) B cells represents ADAM17 (~93kDa, mature f
normalized to actin (~42kDa). N=6 per group total, 4 independent studies.  *indicates 
p<0.05. 
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Reconstitution of irradiated C57Bl/6 WT with combination C57-ADAM10B-/- + TNFKO 
bone marrow rectifies lymph node follicular abnormalities  
In order to assess whether TNF is involved in the mechanism underlying lymph 
node tissue abnormalities in C57-ADAM10B-/- mice, we performed a bone marrow 
chimera experiment in which irradiated CD45.1 WT C57Bl/6 mice were reconstituted 
with one of the following bone marrow combinations: (1) WT (CD45.2) alone; (2) C57-
ADAM10B-/- (CD45.2) alone; (3) TNF deficient (TNFKO) alone; (4) 50/50 mix C57-
ADAM10B-/- + WT (CD45.2); or (5) 50/50 mix C57-ADAM10B-/- + TNFKO.  Following 6 
weeks of reconstitution, mice were bled and analyzed for successful reconstitution and 
CD45.2 cells predominated (Figure 11).  The mice were then footpad immunized with 
NP-KLH, and draining lymph nodes were assessed by immunohistochemistry 14 days 
post-immunization (Figure 12A-H).  As expected, lymph nodes from WT mice 
reconstituted with WT (CD45.2) bone marrow exhibited normal lymph node architecture 
(Figure 12D) and TNF levels (Figure 12G), which was comparable to non-irradiated 
WT nodes (Figure 12A, 12G).  Those reconstituted with C57-ADAM10B-/- bone marrow 
(Figure 12B, 12G), however, had a similar phenotype to those of our C57-ADAM10B-/- 
mice (Figure 7): loss of B cell/T cell segregation, decreased FDC networks, and 
increased cortical TNF.  Those reconstituted with TNFKO bone marrow alone (Figure 
12C) exhibit no TNF staining but do still demonstrate FDC networks as these are 
resistant to irradiation.  Furthermore, reconstitution with 50/50 mix C57-ADAM10B-/- + 
WT CD45.1 still yielded abnormal lymph node architecture (Figure 12E) and high TNF 
staining (Figure 12G) similar to C57-ADAM10B-/-.  Thus, the amount of TNF made by B 
cells from this combination is still too high.  Interestingly, when WT mice were 
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reconstituted with combination C57-ADAM10B-/- + TNFKO bone marrow (Figure 12F, 
12G), lymph node tissue architecture and TNF staining returned to WT levels.  TNF 
staining is further compared and quantified by mean gray values in multiple equal areas 
(at least 6) in Figure 12H.  Here, mice reconstituted with C57-ADAM10B-/- alone as well 
as C57-ADAM10B-/- + WT CD45.1 exhibit significantly more TNF staining compared to 
WT and C57-ADAM10B-/- + TNFKO (Figure 12H).  We reason that while B cells from 
C57-ADAM10B-/- mice produce excessive TNF, those from the TNFKO mice produce 
none, thus averaging to a normal, WT range allowing proper TNF signaling to occur.   
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Figure 11. Confirmation of successful bone marrow reconstitution. 
Irradiated CD45.1 WT mice were reconstituted with CD45.2 (A) or C57-ADAM10B-/- 
(CD45.2) (B) bone marrow and peripheral blood sample collected at 6 weeks post 
reconstitution. Percentage of CD45.2+ live peripheral blood lymphocytes is shown. 
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Figure 12. Reconstitution of irradiated WT naïve LNs with ADAM10B-/- + TNFKO 
bone marrow restores normal follicular architecture and rectifies structural 
abnormalities induced by ADAM10B-/- reconstitution alone. 
Draining lymph node sections from non-irradiated WT (A, G (CD45.1 WT)) and 
irradiated CD45.1 WT reconstituted with ADAM10B-/- (B, G (Reconstitution with 
ADAM10KO)), TNFKO (C), WT CD45.2 (D, G (Reconstitution with CD45.2 WT)), 
ADAM10B-/- + WT CD45.1 (E, G (Reconstitution with ADAM10KO and CD45.1 WT)), 
ADAM10B-/- + TNFKO (F, G (Reconstitution with ADAM10KO and TNFKO)) were 
compared in (A-F) with regards to B/T compartmentalization (left column), FDC reticular 
development (middle column), and TNFα staining (right column).  In (A-G) the following 
stains were used: B cells (blue, B220), T cells (red, Thy1.2), Collagen 1 (green), FDCs 
(red, CR1/2), and TNFα (green).  White boxes in (A-F, right column) are magnified in 
(G, left column), with separation of the TNFα labelling (middle column) and 
measurements (histograms, right column). (H) TNFα expression (mean gray values) in 
multiple equal areas (at least 6) have been calculated and the results expressed as 
mean + SD. Using unpaired T test, the p value between CD45.1 WT and reconstitution 
with CD45.2 WT is 0.33; CD45.1 WT and reconstitution with ADAM10KO and TNFKO is 
0.36; and reconstitution with ADAM10KO and ADAM10KO and CD45.1 WT is 0.2. 
Micrographs are representative of at least 3 LNs from 3 independent experiments. 
Scale bar in A-F = 50 mm, in G = 20 mm. 
 
 
 
 
 
Figure 12. Reconstitution of irradiated WT naïve LNs with ADAM10
bone marrow restores normal follicular architecture and rectifies structural 
abnormalities induced by ADAM10
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B-/- reconstitution alone. 
 
B-/- + TNFKO 
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1.3.4 Balb-ADAM10B-/- exhibit reduced antigen specific antibody production and 
GC B cells similar to C57-ADAM10B-/- mice 
 Similar to C57-ADAM10B-/- mice, we characterized antibody production by Balb-
ADAM10B-/- mice following NP-KLH immunization in alum. At day 7 post immunization, 
NP-specific IgM was reduced in Balb-ADAM10B-/- serum and IgG1 was very lowly 
detected (Figure 13A, 13B).  At day 14, NP-specific IgM and IgG1 were significantly 
reduced in Balb-ADAM10B-/- compared to Balb-WT as expected given our results in 
C57Bl/6 mice (Figure 13A,13B).  Given the reduction in class-switched antibody 
production, we next wanted to assess the percentage of GC B cells in the draining LN of 
Balb-ADAM10B-/- compared to WT.  Unlike C57-ADAM10B-/- (Figure 6B), the Balb-
ADAM10B-/- lymph nodes exhibited a normal percentage of GC B cells compared to 
Balb-WT (Figure 13C).  This finding was unexpected given our results in C57-
ADAM10B-/- and thus prompted an architecture analysis of Balb-ADAM10B-/- lymph 
nodes as well as characterization of ADAM17 and TNF production by Balb-ADAM10B-/- 
B cells. 
1.3.5 Th1 and Th2 strain dependent differences in B cell ADAM17 and TNF as well 
as secondary lymphoid tissue architecture following B cell ADAM10 deletion 
Strain dependent differences in B cell TNF and ADAM17 
C57-ADAM10B-/- B cells exhibit a compensatory increase in ADAM17 expression 
and function resulting in excessive TNF cleavage, which provided the mechanism for 
the aberrant secondary lymphoid tissue architecture noted in these mice [31,107] 
(Figure 7-12).  We, therefore, analyzed both TNF and ADAM17 expression and function 
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by Th2 prone Balb/c WT (Balb-WT) and Balb-ADAM10B-/- compared to C57Bl/6 WT 
(C57-WT) and C57-ADAM10B-/- B cells to see if differences in B cell TNF and ADAM17 
exist between strains.  First, sTNF production by Balb-WT and Balb-ADAM10B-/- B cells 
was comparable following in vitro stimulation unlike our previous report in C57Bl/6 
(Figure 14A).  Furthermore, mTNF in stimulated B cells is comparable between Balb-
WT and Balb-ADAM10B-/- but reduced compared to C57-WT and even further reduced 
compared to C57-ADAM10B-/- (Figure 14B).  Similarly to C57, Balb-WT and Balb-
ADAM10B-/- express comparable TNF message in the naïve state (Figure 14C).  Upon 
stimulation, however, Balb-ADAM10B-/- B cells fail to significantly increase TNF 
message above Balb-WT levels unlike C57-ADAM10B-/- B cells (Figure 14C).  
Furthermore, C57-ADAM10B-/- B cells exhibit increased TNF message compared to 
Balb-ADAM10B-/- (Figure 14C).   
 Given that TNF levels were reduced in Balb-ADAM10B-/- compared to C57-
ADAM10B-/- B cells, we next compared the levels of ADAM17 protein and message.  
C57-ADAM10B-/- B cells exhibited increased ADAM17 protein compared to C57-WT, but 
also compared to Balb-WT and most interestingly, Balb-ADAM10B-/- (Figure 15A).  
Furthermore, ADAM17 protein was comparable between Balb-WT and Balb-ADAM10B-/- 
(Figure 15A), which is consistent with TNF production in Figure 14A.  Unlike C57Bl/6, 
ADAM17 message in naïve Balb-WT and Balb-ADAM10B-/- B cells was comparable and 
increased to 2-fold higher expression upon stimulation (Figure 15B).   
Unlike C57-ADAM10B-/-, Balb-ADAM10B-/- exhibit normal secondary lymphoid tissue 
architecture. 
 
 
70 
We previously noted the defects in secondary lymphoid tissue architecture in 
C57-ADAM10B-/- lymph nodes (Figure 7), including aberrant B cell/T cell localization, 
decreased FDC development, excessive collagen deposition, decreased germinal 
center formation, and increased HEV formation, was attributed to increased B cell 
ADAM17 resulting in excessive B cell TNF production and signaling within the follicle 
[31].  Given the marginal changes in TNF (Figure 14) and ADAM17 (Figure 15) in Balb-
ADAM10B-/-, however, compared to C57-ADAM10B-/- [31] (Figures 7-12), we 
hypothesized Balb-ADAM10B-/- lymph nodes would maintain WT architecture.  Indeed, 
Balb-ADAM10B-/- exhibited comparable primary follicular characteristics to C57-WT and 
Balb-WT, including normal B cell/T cell compartmentalization  (Figure 16A), number 
and size of HEVs (Figure 16A), FDC reticular (Figure 16B), and collagen deposition 
(Figure 16B).  Again, C57-ADAM10B-/- lymph node sections are provided as a reference 
as they exhibit a lack of B/T compartmentalization, increased HEVs, minimal CD21+ 
FDC reticula, and excess collagen deposition.  Furthermore, TNF labeling (boxed 
regions of Figure 16C) demonstrated that C57-ADAM10B-/- follicles displayed the 
highest TNF intensity compared to C57-WT, Balb-WT, and Balb-ADAM10B-/- (Figure 
16C), with the latter groups all having comparable TNF staining (Figure 16C), which is 
quantified in Figure 16D.  These results provide further support that excess B cell sTNF 
underlies the aberrant lymphoid tissue architecture in C57-ADAM10B-/- mice and 
demonstrates the inherent difference in B cell ADAM10 and ADAM17 regulation in Th1 
vs. Th2 prone mice.  
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Figure 13. Balb-ADAM10B-/- mice exhibit reduced NP-specific antibody production 
but a normal percentage GC B cells. 
Balb-WT (WT) (white bars) and Balb-ADAM10B-/- (Balb-A10KO) (black bars) were 
immunized i.p. and f.p. with NP-KLH in alum and bled at day 7 and 14 post 
immunization.  Serum levels of NP-specific IgM (A) and IgG1 (B) were determined at 
day 7 and day 14 post immunization.  (C) At day 14, draining axillary LNs were 
analyzed for GC (B220+GL7+) B cells and percentage compared to total B220+ B cell 
population.  Error bars represent SD; *p<0.05, **p<0.005, ***p<0.0005.  
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Figure 14. Differential TNF production and expression in C57Bl/6 and Balb/c 
ADAM10B-/- (A10K0) and WT B cells.   
(A) Supernatants were harvested on day 3 from C57Bl/6 (left) or Balb/c (right) WT 
(white) or A10KO (black) B cell cultures stimulated with LPS + IL-4 and sTNF 
determined by ELISA. (B) Balb/c WT (black), Balb/c A10KO (red), C57Bl/6 WT (green), 
and C57Bl/6 A10KO (blue) B cells stimulated 3 days with LPS + IL4 were analyzed for 
coexpression of TNF using TSA.  (C) Naïve (white) or 3 day stimulated (black) B cells 
were analyzed by qPCR for TNF message normalized to 18s. Data presented as fold 
change of A10KO over WT for C57Bl/6 (left) and Balb/c (right) using the ∆∆Ct method of 
analysis. n = 9 per group, three independent studies. *p < 0.05, **p < 0.005. 
 
 
 
 
 
Figure 15. Increased ADAM17 in C57Bl/6 WT and A10KO over Bal
A10KO, respectively. 
(A) 5 day stimulated B cells were analyzed by western blot (left) for ADAM17 (~93kDa) 
relative to actin (~42kDa) and band densitometry shown (right).  (B) 
expression normalized to 18s for naïve (white) or 3 day stimulated (black) B cells 
presented as fold change of ADAM10
n=9 per group, three independent studies. *p < 0.05, **p < 0.005.  
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b/c WT and 
Relative ADAM17 
KO over WT using the ∆∆Ct method of analysis. 
 
 
 
Figure 16. Balb-ADAM10B-/- lymph nodes exhibit WT architecture unlike C57
ADAM10B-/- nodes. 
Naïve lymph node sections from C57Bl/6 and Balb/c WT (right) and ADAM10
were analyzed for (A) B cell (blue, B220)/T cell (red, Thy1.2) localization and H
formation (green, pNAD); (B) FDC reticula (red,CR1/2) development, collagen (green) 
deposition, and presence of a distinct cortico
Balb-ADAM10B-/- only); (C) TNF staining (green) within B cell (blue, B220) f
regions. (D) Average TNF staining intensity from 12 follicle sections (represented by box 
in (C)), **p<0.005.  Scale bar is 50 µm. Micrographs are representative of at least 3 
LNs. 
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Chapter 4: Th1 and Th2 prone mouse strains and humans exhibit differential B 
cell ADAM10, ADAM17, and TNF levels 
1.4.1. Th2 prone strains (Balb/c, A/J) B cells exhibit increased ADAM10 and 
decreased ADAM17 and TNF compared to those of Th1 prone strains (C57Bl/6, 
SJL/J) 
Based on results described in Figures 14-16, clear differences in TNF and 
ADAM17 exist between C57-WT and Balb-WT B cells.  Therefore, we aimed to confirm 
if differences in TNF, ADAM10, and ADAM17 exist between other Th1 and Th2 prone 
strains.  Because Th2 prone mouse strains are more susceptible to models of airway 
hyper-reactivity and increased B cell ADAM10 correlated with exacerbated airway 
symptoms and immunopathology in mice, we hypothesized that Th2 prone mouse 
strains would exhibit increased B cell ADAM10 and reduced ADAM17 and TNF 
compared to Th1 counterparts [180].  In fact, naïve B cells from Th2 prone Balb/c and 
A/J expressed higher total ADAM10 (Figure 17A) and decreased total ADAM17 (Figure 
17B) compared to Th1 prone C57Bl/6 and SJL/J.  Upon stimulation in vitro, B cells from 
the chosen Th1 prone strains expressed increased mTNF compared to the chosen Th2 
prone strains (Figure 17C).  Furthermore, TNF message was lower in Th2 prone A/J 
and Balb/c mice compared to C57Bl/6 WT by ≥2 fold (Figure 17D).  C57Bl/6 WT TNF 
expression was not significantly different from SJL/J (Figure 17D).  B cell ADAM10 in 
both Th1 prone-C57Bl/6 and Th2 prone-Balb/c strains increased following in vitro 
stimulation (Table 4).  However, Th2 prone Balb/c maintained a consistently higher 
level of B cell ADAM10 even after equal stimulation (Table 4).  This finding 
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demonstrates that T cell help, in the form of anti-CD40/IL-4 or anti-CD40 alone, 
augments ADAM10 expression but does not provide the entire explanation for why B 
cell ADAM10 is initially increased in Th2 prone over Th1 prone strains.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17.  Increased B cell ADAM10 and decreased ADAM1
biased strains.  
Naïve B220+ B cells (A, B) stained for total ADAM10 (A) or ADAM17 (B) expression by 
flow cytometry. (C) Surface TNF 
B cell by TSA. (A,B,C) Bar graph represents percent total B cells staining high in 
ADAM10 (A), ADAM17 (B), or TNF (C). (A,B,C) Balb/c (
SJL (▪▪▪▪▪), respective isotype control (shaded grey) in representative overlay (left); grey 
gate demonstrates high stained population. n = 8 per group, 3 independent studies. 
*p<0.05, **p<0.005, ***p<0.0005. (D) TNF message from 3 day stimulated (anti
IL4) B220+ B cells. Presented as fold change from C57Bl/6 WT. * signifies 
change between groups.   
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Table 4.   ADAM10 expression in Naïve and Stimulated WT B cells by qPCR.  
Comparison Average Fold Change in ADAM10 
mRNA expression (±SD) using 
∆∆Ct 
Balb naïve / C57 naïve 2.35 ± 1.00  
Balb A+I / Balb naïve  2.02 ± 0.66 
C57 A+I / C57 naïve  2.40 ± 1.34 
Balb A / Balb naïve  2.88 ± 1.45 
C57 A / C57 naïve  1.91 ± 0.30 
Balb A+I / C57 A+I 5.34 ± 1.84 
Balb A / C57 A 5.70 ± 1.45 
A+I (3 days stimulation with anti-CD40+IL4); A (3 day stimulation with anti-CD40 alone). 
ADAM10 expression normalized to 18s. Fold change in gene expression of 2 or more 
between groups considered significant. 
 
 
 
 
 
 
 
 
 
 
79 
1.4.2 High B cell ADAM10 predicts increased susceptibility to Th2 disease 
High B-ADAM10 level in the context of a Th2 environment allows optimal induction of 
allergic airway disease symptoms 
C57Bl/6 WT exhibit a decreased response to mouse lung inflammation models 
compared to Balb/c including airway bronchoconstriction and IgE production, however, 
these findings have never been linked to B cell ADAM10 levels, specifically 
[31,181,182].  Our results thus far indicate that Th2 prone mice, whose B cells are 
known to produce excess IgE post immunization, exhibit increased B cell ADAM10 even 
in a naïve, non-stimulated state.  After stimulation with anti-CD40/IL-4 (Table 4), B cell 
ADAM10 levels increased more dramatically in Th2 prone strain B cells as well.  
Therefore, we next sought to compare the consequences of B cell ADAM10 level in the 
context of a Th1 or Th2 immune-environment on acute airway hypersensitivity induction 
following house dust mite (HDM) challenge (Figure 18), specifically with regards to IgE 
production.  The groups considered included: B cell ADAM10 high, Th2 prone (Balb/c 
WT); B cell ADAM10 low, Th1 prone (C57 WT); B cell ADAM10 deleted, Th2 prone 
(Balb-ADAM10B-/-); and B cell ADAM10 deleted, Th1 prone (C57-ADAM10B-/-).  When 
each group was treated intranasally with saline, all disease parameters were similar (not 
statistically different).  For clarity, saline treated Balb WT was chosen as the 
representative saline group in Figures 19 and 20.    
Th2 prone, B cell ADAM10 high Balb WT exhibit the most severe induction of 
lung inflammation following HDM challenge, including increased bronchoconstriction 
(Figure 19A) and inflammatory, cellular infiltrate in lung tissue (boxed regions at 10x 
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magnification in Figure 20A, 20C).  Similarly, Balb WT exhibit the highest goblet cell 
metaplasia as indicated by the intense pink staining mucin (arrows in Figure 20B) and 
mucus (MUC5AC protein) production (Figure 20D).  Furthermore, the thickness of the 
alveolar epithelium (Figure 20B) is greatest in the Balb/c compared to other groups with 
the C57-ADAM10B-/- being reflective of saline controls.  In accordance with our main 
hypothesis that increased B cell ADAM10 lends to increased IgE production, Balb WT 
exhibited the highest HDM-specific IgE (Figure 19C) as well.  When ADAM10 is deleted 
from B cells but remains in the context of a Th2 environment in the Balb-ADAM10B-/-, 
bronchoconstriction (Figure 19A), goblet cell hyperplasia (Figure 20B), and mucus 
production (Figure 20D) are reduced significantly from Balb WT and are quite similar to 
the Th1 prone, B cell ADAM10 low C57-WT.  Furthermore, HDM-specific IgE (Figure 
19C) is reduced from Balb WT levels demonstrating the critical importance of B cell 
ADAM10 for IgE production even in a Th2 prone environment.  Lastly, B cell ADAM10 
deletion in the context of a Th1 environment (C57-ADAM10B-/-) provides the least 
suitable context for allergic airway disease induction.  Thus, as indicated previously, 
C57-ADAM10B-/- mice exhibited bronchoconstriction (Figure 19A), cellular infiltration of 
lung tissue (Figure 20A, 20C), goblet cell metaplasia (Figure 20B), and mucus 
production (Figure 20D) similar to saline control.  While the HDM-specific IgE ELISA 
was not sensitive enough to detect differences between saline, C57-WT, and C57 and 
Balb-ADAM10B-/-, it does indicate the importance of both ADAM10 and strain 
background in IgE production as both the Balb-ADAM10B-/- and C57-WT demonstrated 
significantly reduced HDM-specific IgE production compared to Balb WT (Figure 19C).  
Although anticipated, this is the first time reduced IgE production has been 
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demonstrated in both C57 and Balb-ADAM10B-/- mice.  Furthermore, B cell ADAM10 
deletion from Balb or C57 fails to reduce eosinophil recruitment in BALF, but it appears 
to be a strain dependent phenomena as Balb/c mice regardless of B cell ADAM10 
presence had increased eosinophils compared to C57 WT and C57-ADAM10B-/- (Figure 
19B). 
Allergic patients exhibit increased B cell ADAM10, CD23 cleavage, and IgE yet reduced 
ADAM17 and TNF 
Our results thus far indicate that mouse strains with higher B cell ADAM10 have 
increased susceptibility to airway hyperreactivity induction, especially when in a Th2 
context.  Furthermore, B cells from Th2 prone strains exhibit increased B cell ADAM10 
and reduced ADAM17 and TNF.  In humans, we define “Th2 context” as patients 
actively suffering from allergic rhinitis, a Th2 disease.  Our goal was to characterize the 
B cell phenotype of active allergic rhinitis patients and compare it to patients without a 
history of atopic disease (controls).  Naïve peripheral B cells from 16 allergic patients 
exhibited significantly increased B cell ADAM10 compared to 16 controls (Figure 21A) 
by flow cytometric analysis.  Contrastingly, peripheral blood T cells (Figure 21B) and 
monocytes (Figure 21C) from allergic and control patients revealed comparable 
ADAM10 expression.  Thus, only B cell ADAM10 expression served as an allergy-
associated differential indicator.  Following 5 days of stimulation in vitro with IL-21/IL-
4/anti-CD40, allergic-B cell supernatants demonstrated increased sCD23 indicating 
higher ADAM10 activity in allergic patient B cells compared to controls (Figure 21D).  
This finding supports a previous report that demonstrated increased circulating sCD23 
in allergic patient’s sera [183].  Furthermore, B cell ADAM10 message in allergic 
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patients was increased nearly 5-fold, while ADAM17 and TNF message were decreased 
2-fold compared to controls (Figure 21E).   
Given that increased B-ADAM10 leads to increased IgE production through 
CD23 cleavage [30], we next compared serum antigen-specific IgE between allergic 
and control patients.  We were reliant on each patient self-reporting a specific antigen to 
which he/she was allergic in order to perform an antigen specific ImmunoCAP [184].  
Five of 16 allergic patients self-reported HDM sensitivity and ImmunoCAP demonstrated 
positive HDM specific IgE levels (>0.35 kuA/I) (Figure 21F).  Five control patients, who 
are also quite likely exposed to HDM daily but do not develop allergy, demonstrated 
negative ImmunoCAP results (all <0.35 kuA/I) or very low levels (0.41kuA/l) (Figure 
21F).  We next compared each individual patient’s HDM-specific IgE result to his/her 
respective B cell ADAM10 expression (Table 1).  In general, all control patients 
exhibited very low or negative HDM specific IgE and low ADAM10 expression (< 25%) 
(Table 5).  As HDM specific IgE levels increased, B cell ADAM10 expression also 
increased in allergic patients. One allergic patient, however, had a lower HDM specific 
IgE result at 5.4 kuA/l but demonstrated a high B cell ADAM10 level (69%) (Table 5).  
Overall, Figure 21 and Table 5 demonstrates a correlation between increased serum 
antigen-specific IgE and increased B cell ADAM10 in allergic patients.   
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Figure 18. HDM lung inflammation protocol.  
Mice were intranasally (I.N) exposed to HDM or saline (black arrow) and on day 15 
analyzed for AHR, BALF cell distribution, and lung tissue was collected for sectioning. 
 
 
 
 
 
 
 
 
 
Figure 19. B cell ADAM10 deletion attenuates bronchoconstriction and HDM 
specific IgE.  
 
Airway resistance (cmH20.s/mL) with increasing doses of methacholine (left); Balb
(──,○), Balb-ADAM10B-/-(----
(──,●) presented as fold increase from saline control. All mice immunized with saline 
demonstrated comparable results.  For simplicity, saline represents Balb WT mice given 
saline.  Bar graph (right) represents 25 mg/mL methacholine dose. (B) Percent 
macrophages (left) and eosinophils (right) from total BALF determined by flow 
cytometry; Saline control (white), Balb WT (checkered), Balb
WT (slash), and C57-ADAM10B
group, 3 independent experiments. *p<0.05, **p<0.005, ***p<0.005.
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Figure 20. B-ADAM10 deletion reduces cellular infiltration, goblet cell metaplasia, 
and mucus production in a strain dependent manner. 
(A) H&E stain for lung tissue demonstrates inflammatory cellular infiltration (red box); 
10x magnification, scale bar 200 µm.  (B) Goblet cell metaplasia determined by PAS 
stain; note dark pink mucin producing cells (black arrow) and alveolar epithelium 
thickness; 20x magnification, scale bar 100 µm. (C) Lung pathology score representing 
quantitation of inflammatory cellular infiltration on H&E stained lung sections; 2 sections 
per mouse and at least 4 mice per group were assessed. (D) MUC5AC protein. n=7
per group, 3 independent experiments. All mice immunized with saline demonstrated 
comparable results.  For simplicity, saline represents Balb WT mice given saline.   
*p<0.05, **p<0.005.   
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Figure 21: Allergic patient B cells exhibit increased ADAM10 and sCD23
decreased ADAM17 and TNF.
(A) Total ADAM10 in naïve CD19
(bold line, black dot) patients; dot plot (right) shows percent of total B cells staining high 
in ADAM10 (grey gate). Isotype control is shaded grey in histogram.  (B,C) Total 
ADAM10 on naïve T cells (B) and monocytes (C). (D) sCD23 from control (open dot) or 
allergic (black dot) supernatants. (E) Naïve B cells from 4 allergic and 4 control patients 
analyzed for ADAM10, ADAM17, and TNF message normalized to GAPDH. 
Significance (*) indicates ≥ 2 fold c
in sera of control (open dot) or allergic (black dot) patients determined by ImmunoCAP. 
<0.35kuA/l considered a negative result. *p<0.05, **p<0.005, ***p<0.0005.
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Table 5. Increased HDM specific IgE correlates with increased B cell ADAM10 
expression. 
Control Allergic 
HDM Specific IgE 
(kuA/l) 
Percent 
CD19+ADAM10high 
HDM Specific IgE 
(kuA/l) 
Percent 
CD19+ADAM10high 
<0.35 13 5.4 69 
<0.35 18 12.8 48 
<0.35 22 15.0 51 
<0.35 25 18.0 60 
0.41 15 22.0 72 
Direct comparison of individual patient’s HDM specific IgE determined by ImmunoCAP 
and B cell ADAM10 expression determined by flow cytometry.   
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Chapter 5: C57-ADAM10B-/- B cells exhibit a B10 phenotype with enhanced ICOSL 
expression and induction of T regulatory cells in secondary lymphoid tissues. 
While excessive B cell TNF explained the mechanism underlying aberrant 
secondary lymphoid tissue architecture in C57-ADAM10B-/-, it does not explain the 
deficit in class-switched antibody production post immunization because both C57 and 
Balb-ADAM10B-/- mice demonstrated reduced antibody levels (Figures 4 and 13).  
Therefore, we next sought to explain the mechanism by which loss of B cell ADAM10 
causes reduced antigen-specific antibody production.   
1.5.1 Increased B10 cells in C57-ADAM10B-/- mice 
 B10 cells are a unique subset of B cells that produce the anti-inflammatory 
cytokine, IL-10.  Classically, their surface markers are defined as CD1d+CD5+IgDloIgMhi 
or B220+IL-10+ [145].  Maseda et al. described that of the B10 cell population, only a 
subset will become antibody secreting plasma cells [164].  Given the reduction in 
antibody production in C57-ADAM10B-/- mice, we hypothesized that a larger portion of 
their B cells may be B10 cells.  We used flow cytometry to assess the percentage of 
B220+IL-10+ B cells present following 3 days of stimulation in vitro with anti-CD40/IL-4.  
Of the total B220+ B cell population, 30% of C57-ADAM10B-/- B cells expressed IL-10 
compared to only 10% of WT B cells (Figure 22A).  We chose not to define B10 cells as 
CD1d+CD5+IgDloIgMhi because these markers overlap with MZ B cell markers and the 
C57-ADAM10B-/- mice lack MZ B cells [52], which may affect interpretation of the data.  
Furthermore, soluble IL-10 production by 3 day stimulated (anti-CD40/IL-4) C57-
ADAM10B-/- B cells was 3 fold higher compared to WT (Figure 22B).  While B cell IL-10 
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message was comparable in naïve WT and C57-ADAM10B-/- B cells, following in vitro 
stimulation (anti-CD40/IL-4) for 5 days, IL-10 message increased to 6.37 fold higher in 
C57-ADAM10B-/- B cells over WT (Figure 22C).  We next assessed the presence of IL-
10 in circulation.  In naïve mice, IL-10 was below levels of detection in both WT and 
C57-ADAM10B-/- mice (Figure 22D).  14 days post immunization with NP-KLH in alum, 
however, IL-10 levels rose to ~ 60 ng/mL in C57-ADAM10B-/- serum, which is 6 fold 
higher than WT (Figure 22E).   
1.5.2 Increased T regulatory cells in ADAM10B-/- mice 
 B cells alone are not normally thought to produce such high levels of IL-10 as 
noted in Figure 22E.  Treg cells, however, are a well-known IL-10 producing cell type 
that may contribute to the very high levels of IL-10 seen.  Furthermore, some reports 
state that B10 cells enhance Treg development and function [161–163].  For these 
reasons, we hypothesized that C57-ADAM10B-/-mice have increased Treg cells in 
secondary lymphoid tissues, which may be explained at least in part by more B10 cells. 
Immunohistochemistry revealed an increase in CD3+FoxP3+ cells in C57-ADAM10B-/- 
spleen 14 days post immunization with NP-KLH in alum (Figure 23A and 23B).  While 
we are still working to optimize our staining of FoxP3+ Tregs by immunohistochemistry, 
the single color sections (Figure 23A, bottom) clearly demonstrate an increase in 
FoxP3+ staining in C57-ADAM10B-/- spleen.  This finding was confirmed by flow 
cytometry, which demonstrated increased Tregs using two conventional sets of markers 
(CD4+CD25+ and CD4+FoxP3+) in both naïve (Figure 24A and 24B) and 14 day 
immunized (Figure 24C) C57-ADAM10B-/- spleen.     
 
Figure 22. C57-ADAM10B-/- B cells have a B regulatory or B10 cell phenotype and 
C57-ADAM10B-/- mice exhibit increased IL10 in circulation
(A, B) 3 day stimulated (anti-CD40/IL
flow cytometry and (B) IL10 secretion by ELISA. 
3 day stimulated (anti-CD40/IL
or (E) 14 days post immunization with NP
ELISA. (A, B, E) *p<0.05; (C) * signifies 
90 
. 
-4) B cells have increased (A) IL10 expression by 
(C) IL-10 message in naïve (white) and 
-4) (black) B cells.  Serum collected from (D) naïve mic
-KLH for determination of circulating IL
≥ 2 fold change between WT and A10KO.
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Figure 23. Increased FoxP3+ T cells in 14 day immunized C57-ADAM10B-/- spleen. 
(A) C57-WT (left) and A10KO (right) spleens stained for B cells (B220), T cells (CD3) 
and FoxP3 (green). Threshold single color sections with outline (cell) counting shown 
below. (B) Percent CD3+FoxP3+ compared to CD3+ alone shown in bar graph. 
Representative of 3 mice/group. *p<0.02 
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Figure 24. Increased Tregs in C57-ADAM10B-/- naïve and immunized spleen. 
(A, B) Naive and (C) 14 day immunized spleen from WT (white, thin black line) or 
A10KO (black, thin red line) were analyzed for Tregs using two surface marker 
combinations: CD4+CD25+ (A,C) and CD4+FoxP3+ (B). (C) A representative overlay of 
CD4+CD25+ Tregs; isotype control shaded grey; marker gate demonstrates high 
staining CD25+ population.  *p<0.05, **p<0.005.    
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1.5.3 Increased ICOSL expression on C57-ADAM10B-/- B cells 
 Given that we are using a B cell specific knockout model characterized by 
increased B cell ADAM17 activity, we hypothesized that a B cell associated ADAM17 
substrate or ADAM17-regulated ligand may be involved in increasing Treg development 
and persistence.  It is known that blockade of ICOS-ICOSL interactions in vitro impairs 
Treg induction [113] and that ICOS deficiency leads to FoxP3+ Treg apoptosis and 
impaired IL-10 production [114].  Furthermore, Marczynska et al. demonstrated that 
ADAM17 indirectly decreases surface ICOSL and increases sICOSL production [112].  
Given that C57-ADAM10B-/- B cells exhibit increased ADAM17 activity, we analyzed 
ICOSL surface expression.  We found that naïve C57-ADAM10B-/- B cells have 
significantly increased ICOSL expression compared to naïve WT B cells (Figure 25A).  
Even though C57-ADAM10B-/- B cells have increased ADAM17, this ADAM17 is not yet 
active until the B cell is stimulated.  Following PMA stimulation in vitro to activate 
ADAM17 activity, we tracked ICOSL cleavage kinetically and found that ICOSL levels 
decrease more dramatically in C57-ADAM10B-/- B cells at each time point compared to 
WT (Figure 25B).  Furthermore, while C57-ADAM10B-/- B cell ICOSL levels remained 
very low at later time points, it appears that WT B cell ICOSL expression begins to 
increase slightly starting at 60 minutes.  Therefore, C57-ADAM10B-/- B cells may have a 
deficient recovery of ICOSL surface levels (Figure 25B).  Figure 22A demonstrated 
that 30% of stimulated C57-ADAM10B-/- B cells are IL-10 producing, B10 cells.  Given 
that ICOSL is increased on C57-ADAM10B-/- B cells and 30% of these are B10 cells, 
ICOSL may be a potential marker for B10 cells.  To verify this point, we plan to stain 
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B220+ cells for IL-10 and ICOSL concomitantly to verify if IL-10 producing cells express 
more ICOSL than non-IL-10 producing B cells.   
1.5.4 Conditioned C57-ADAM10B-/- B cell supernatants cause enhanced Treg 
induction in vitro 
 The next central question is what the C57-ADAM10B-/- B cell is expressing or 
producing that is causing an induction of Tregs.  We used an in vitro Treg induction 
protocol [165] to see if soluble factors released during 5 days of B cell culture with anti-
CD40 and IL-4 would induce FoxP3 expression in CD4+CD25- T cells.  We isolated 
CD4+CD25- T cells and cultured them in one of the following conditions: (1) media 
alone (with IL-2/anti-CD3/CD28 co-stimulation) (negative control), (2) + recombinant 
TGFβ alone (positive control), (3) + conditioned WT B cell supernatant, or (4) + 
conditioned C57-ADAM10B-/- B cell supernatant.  While recombinant TGFβ caused 
~72% of T cells to become FoxP3+, conditioned C57-ADAM10B-/- supernatants resulted 
in ~50% and WT supernatant ~12% (similar to media alone) induction of FoxP3 
expression (Figure 26).  We are currently testing anti-ICOSL and anti-IL10 neutralizing 
antibodies in vitro to see if neutralization of either or both together will block FoxP3 
induction in CD4+CD25- T cells.  Furthermore, we are testing PMA stimulated WT and 
C57-ADAM10B-/- B cell supernatants to see if PMA stimulation of B cells results in more 
FoxP3 induction when the supernatants are cultured with CD4+CD25- T cells.  We 
predict there will be more induction since PMA is far better at activating ADAM17, which 
we believe is controlling release of a soluble molecule (e.g. ICOSL) that is ultimately 
responsible for induction of FoxP3 expression.   
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As a preliminary study, we analyzed FoxP3 expression by qPCR in CD4+CD25- 
T cells cultured with 2 hour PMA-stimulated WT or C57-ADAM10B-/- B cell supernatant 
with and without ICOSL neutralizing antibody, which prevents ICOSL binding to the 
ICOSR (Figure 27).  Compared to CD4+CD25- T cells treated with media alone, those 
cultured with C57-ADAM10B-/- B cell supernatant increased FoxP3 expression by 12 
fold, which was reduced to 7 fold by the addition of ICOSL neutralizing antibody (Figure 
27).  Interestingly, however, WT supernatant alone still induced FoxP3 expression 7 
fold, which we believe may be do to PMA remaining in the B cell supernatant (Figure 
27).  Therefore, we must perform a PMA only control to see if PMA alone induces 
FoxP3 expression in CD4+CD25- T cells.  According to Majowicz et al., CD4+CD25- T 
cells cultured with PMA and anti-CD3 increased FoxP3 and CD25 expression [185].  
Therefore, we may need to remove the PMA with dextrin labeled charcoal before the 
co-culture.  We can confirm PMA is removed by performing a CD62 ligand kinetic 
shedding assay in which the supernatants with and without PMA removed are assessed 
for their ability to induce CD62 ligand shedding from WT B cells.  Furthermore, we will 
culture WT or C57-ADAM10B-/- supernatants with an isotype control antibody to validate 
our ICOSL neutralizing antibody results.    
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Figure 25. Increased ICOSL expression and cleavage on C57-ADAM10B-/- B cells. 
(A) Representative overlay of baseline ICOSL expression in naïve WT (black solid) and 
C57-ADAM10B-/- splenic B cells (red). Unstained (thin dashed) and isotype control (thick 
black dashed) shown.  (B) ICOSL expression on WT (open dot) and C57-ADAM10B-/- B 
cells (black dot) following PMA stimulation vitro. 
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Figure 26. C57-ADAM10B-/- conditioned B cell supernatants induce enhanced 
FoxP3 expression in CD4+CD25- T cells compared to WT B cell supernatants.  
4 day stimulated CD4+CD25- T cells with cultured with IL-2/CD3/CD28 alone (green) or 
IL-2/CD3/C28 plus 5 day conditioned (anti-CD40/IL-4) WT B cell supernatant (black), 5 
day conditioned (anti-CD40/IL-4) A10KO B cell supernatant (red), or rTGFβ (purple).  
Representative overlay of changing FoxP3 expression (left) and dot plots (right) 
demonstrate percent CD4+FoxP3+ T cells following culture with rTGFβ (purple) or WT 
(black) or A10KO (red) 5 day conditioned B cell supernatants.  
 
CD4
F
o
x
P
3
-10
1
10
2
10
3
10
4
10
5
-10
2
10
2
10
3
10
4
10
5
21.07%2.03%
72.70%4.21%
 
 
 
Figure 27.  ICOSL neutralization reduces Fox
CD4+CD25- T cells with PMA
WT (white) or C57-ADAM10B-
Conditioned supernatants with (striped) or without (solid) anti
antibody (aICOS) or media alone (containing IL
CD4+CD25- T cells for 4 days with plate
relative to GAPDH was assessed and 
expression when cultured with media
significant.  Fold change calculated using 
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P3 expression in co-cultures of 
-conditioned C57-ADAM10B-/- B cell supernatants.  
/- (grey) B cells were cultured for 2 hours with PMA.  
-ICOSL neutralizing 
-2) were collected and cultured with 
-bound CD3 and CD28.  FoxP3 expression 
data presented as fold change from FoxP3 
 alone.  A fold change of ≥2 is considered 
∆∆Ct equation.     
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1.5.5. In vivo Treg depletion studies  
 Our next goal was to see if increased Treg cells played a functional role in the 
C57-ADAM10B-/- phenotype.  Specifically, is increased Tregs the mechanism underlying 
decreased antigen-specific antibody production and reduced disease parameters 
following HDM immunization?     
HDM acute airway hypersensitivity studies with Treg depletion 
 In vivo depletion of CD4+CD25+FoxP3+ Treg cells can be achieved using anti-
CD25 (PC61mAb).  Setiady et al. described that Treg depletion with anti-CD25 is 
FcγRIII dependent as FcγRIII deficient mice were resistant to Treg depletion with anti-
CD25 [186].  Furthermore, it was FcγRIII+ macrophages, but not FcγRIII+ NK cells, that 
were critical for antibody-mediated phagocytosis [186].  WT or C57-ADAM10B-/- mice 
were injected i.p. 3 days before and 3 days after the first intranasal HDM challenge to 
effectively deplete Tregs.  The acute HDM challenge protocol was performed exactly as 
described in Figure 18.  All mice treated with saline regardless of i.p. injection (PBS, 
COH2, anti-CD25) had statistically comparable disease parameters and are shown in 
Figures 27 and 28 as a representative saline group.  Similar to our previous results in 
Figure 19, C57-ADAM10B-/- mice treated with COH2/HDM exhibit AHR comparable to 
saline treated mice (Figure 28A).  Furthermore, COH2/HDM treated WT mice have 
increased AHR compared to both C57-ADAM10B-/- COH2/HDM and saline control 
(Figure 28A).  Interestingly, anti-CD25/HDM treated C57-ADAM10B-/- mice have 
increased AHR compared to COH2/HDM treated C57-ADAM10B-/- mice and it is 
comparable to COH2/HDM treated WT mice (Figure 28A).  Anti-CD25/HDM treated WT 
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mice exhibit the highest AHR, which is consistent with previous reports that Tregs are 
important for regulating AHR in murine HDM models [139–141].  Overall, depletion of 
Tregs in C57-ADAM10B-/- mice increased AHR.  
 Total cell number in BALF increased with anti-CD25 treatment compared to 
COH2 and PBS.  While this increase was significant in WT, it trended upward in C57-
ADAM10B-/- mice (Figure 28B).  When comparing the BALF cell differential, specifically 
eosinophils, varied between COH2 and anti-CD25 treated groups (Figure 28C).  
Treatment with anti-CD25/HDM increased eosinophils in both WT and C57-ADAM10B-/- 
mice compared to COH2/HDM treatment (Figure 28C).  In Figure 19B, there was not a 
statistical difference between HDM treated WT and C57-ADAM10B-/- mice, however 
there was a trend toward reduced eosinophils as is shown in Figure 28C.   
Furthermore, H&E stained lung sections were assessed from each group for both 
perivascular and peribronchiolar inflammatory cellular infiltration.  Intraperitoneal 
injection of PBS, COH2, or anti-CD25 did not result in inflammatory cellular infiltration 
as all saline treated groups lacked peribronchiolar or perivascular cell infiltration (Figure 
29, top row).  Anti-CD25/HDM treatment increased both perivascular and peribronchilar 
inflammatory cellular infiltration in both WT and C57-ADAM10B-/- mice compared to 
COH2/HDM treatment (Figure 29).  Therefore, Treg depletion results in increased 
peribronchiolar and perivascular inflammatory cellular infiltration.  PAS stained lung 
sections were analyzed for mucin production, which stains bright pink when positive.  
Saline treated mice were negative for mucin staining as was COH2/HDM treated C57-
ADAM10B-/- lung sections (Figure 30).  Similar to Figure 20, COH2/HDM treated WT 
mice had increased mucin compared to COH2/HDM treated C57-ADAM10B-/- (Figure 
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30, middle row).  Interestingly, mucin staining increased in both WT and C57-
ADAM10B-/- treated with anti-CD25/HDM (Figure 30, bottom row).  Furthermore, the 
number or extent of bronchi staining positive for mucin increased as well.  Currently, we 
are in the process quantifying mucin production.   
 Lastly, HDM-specific IgE was assessed with and without Treg depletion.  
Consistent with previous results (Figure 19C), COH2/HDM treated C57-ADAM10B-/- 
mice produce significantly less HDM-specific IgE compared to COH2/HDM treated WT.  
Interestingly, anti-CD25 treatment increased HDM-specific IgE in C57-ADAM10B-/- mice 
to WT levels (Figure 28D).  HDM-specific IgE levels in anti-CD25 treated WT mice also 
trended upward compared to WT treated with COH2.  Figure 28D is critically important 
for understanding the phenotype of C57-ADAM10B-/- mice.  It demonstrates that 
increased Tregs in C57-ADAM10B-/- mice plays a central role in reducing antigen 
specific Ig production.  It is likely, however, that increased Tregs along with other factors 
provide a complete explanation for the phenotype.  One additional factor perhaps is that 
a greater percentage of B220+ B cells are IL-10 producing B10 cells, which are less 
adept at producing class switched antibody.    
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Figure 28.  Treg depletion in C57-ADAM10B-/- prior to HDM challenge increases 
AHR, BALF cellularity, eosinophil infiltration, and HDM-specific IgE. 
 (A) Airway resistance following increasing doses of methacholine. Bar graph (right) 
demonstrates airway resistance at 25 mg/mL methacholine dose. (A) Total BALF cells 
normalized to 100µL volume. Anti-CD25/HDM treated (black) and COH2/HDM treated 
(checkered). (C) BALF cell differential; eosinophils (black), PMN (white), lymphocytes 
(horizontal striped), and mononuclear cells (vertical striped).  (D) HDM-specific IgE 
determined by ELISA. *p<0.05, **p<0.005. 
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Figure 29.  Treg depletion increases peribronchiolar and perivascular 
inflammatory cellular infiltration in WT and C57-ADAM10B-/-. 
Representative H&E stained lung sections demonstrating peribronchiolar (thin arrow) 
and perivascular (thick arrow) inflammatory cellular infiltration.  Note the differences in 
the thickness of rings of inflammatory cell as well. All 10x magnification, scale bar 200 
µm. Representative of 2 lung sections per mouse and 3 mice per group.   
C57 WT C57 ADAM10B-/- 
Saline 
COH2/
HDM 
Anti-CD25/
HDM 
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Figure 30.  Anti-CD25 treatment increases mucin in WT and C57-ADAM10B-/- 
airways.  
Representative PAS stained lung sections demonstrating the presence of dark pink 
staining mucin (arrow).  All at 20x magnification, scale bar 100 µm. Representative of 2 
lung sections per mouse and 3 mice per group.   
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1.5.6 Other unique features of ADAM10B-/- B cells  
C57-ADAM10B-/- B cells have other unique properties that may also affect their 
ability to effectively produce antibody.  Naïve B cells should be CD43 negative and upon 
activation CD43 expression increases.  When trying to isolate CD43 negative B cells by 
magnetic bead isolation (CD43 depletion), significantly fewer B cells were recovered 
from C57-ADAM10B-/- compared to WT.  This led us to investigate CD43 expression 
levels on C57-ADAM10B-/- B cells.  Figure 31 demonstrates that naïve B cells isolated 
from C57-ADAM10B-/- spleen and lymph node have increased CD43 expression in the 
naïve state.  Increased B cell activation markers suggests that C57-ADAM10B-/- B cells 
are in a pre-activated state and may be refractory to subsequent stimulation.  If so, this 
finding may help explain reduced antibody production and other B cell defects seen in 
these mice.   
Furthermore, C57- ADAM10B-/- B cells fail to reconstitute the secondary lymphoid 
organs of B cell deficient mice as effectively as WT B cells (Figure 32A and 32B).  
C57Bl/6 B cell deficient mice were reconstituted i.v. with WT or C57- ADAM10B-/- B cells 
and subsequent B cell reconstitution of secondary lymphoid organs was assessed 2 
weeks post immunization.  Figure 32 demonstrates that B cell reconstitution of both LN 
and spleen was reduced nearly 3 fold in C57- ADAM10B-/-.  While the mechanism 
underlying this phenomena is still under investigation, some potential options are (1) 
C57- ADAM10B-/- B cells simply take longer to reconstitute lymphoid tissues than WT; 
(2) Differential signaling or lack of chemokine signaling slows or prevents their 
reconstitution; or (3) C57- ADAM10B-/- are pre-activated (Figure 31) and may exhibit a 
shorter half-life causing high B cell turnover before our 2 week assessment.  
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Figure 31. Increased CD43 expression on C57-ADAM10B-/- B cells.  
CD43 expression in naïve, B220+ B cells isolated from LN (left) and spleen (right) of WT 
(black) and C57-A10KO (red) mice.  Gate represents population staining negative and 
low in surface CD43. 
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Figure 32. C57-ADAM10B-/-B cells fail to reconstitute secondary lymphoid tissues 
as effectively as WT B cells. 
Following 2 weeks of reconstitution with either WT (white) or A10KO (black) B cells, 
percent B220+ B cells in LN (A) and spleen (B) of B cell deficient mice was determined 
by flow cytometry.  
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Chapter 6: Discussion 
1.6.1 Increased ADAM17 and excessive B cell sTNF production provides the 
mechanism for aberrant secondary lymphoid tissue architecture in C57-ADAM10B-
/- mice 
 Chaimowitz et al. noted two key immune system alterations in C57-ADAM10B-/- 
mice; however, no mechanism was described [107].  First was that lymph node tissue 
architecture is disrupted 14 days post immunization with T-dependent antigen including 
aberrant B cell/ T cell localization, reduced GC formation, and reduced FDC network 
development [107].  Architecture studies herein, further, describe secondary lymphoid 
tissue alterations in naïve lymph nodes from C57-ADAM10B-/- mice as well (Figure 7).  
Their naïve lymph nodes exhibited aberrant B cell/ T cell localization, reduced FDC 
network development, reduced GC formation, increased HEV size and number, fibrosis, 
and increased TNF staining in B cell follicle regions [31].  Furthermore, we demonstrate 
herein key phenotypic characteristics of C57Bl/6 ADAM10 deficient B cells including 
increased ADAM17 expression and function (Figure 15), which resulted in enhanced 
TNF message, surface expression, and soluble production (Figure 14).     
Three TNF family cytokines, TNF, LTα, and LTβ, are classically studied in 
secondary lymphoid tissue architecture maintenance.  While ADAM17 is most notably 
studied as the TNF sheddase, one study demonstrated that ADAM17 can cleave 
membrane bound LTα1β2 heterotrimer on T cells in vitro and this cleavage is blocked 
by the ADAM17 inhibitor, TAPI-1 [100].  These structurally homologous and genetically 
linked cytokines have been studied individually and as double deficient mouse models, 
in an attempt to tease out the contributions of each to secondary lymphoid tissue 
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microarchitecture development and maintenance [187].  LTα deficient mice lack lymph 
nodes and Peyer’s patches and exhibit abnormal splenic architecture including loss of 
B/T segregation and a complete absence of FDC networks, germinal center formation, 
and marginal zone B cells [101,102].  LTα as a soluble homotrimer (LTα3) is also known 
to play an integral role in lymphoid organization including B/T segregation by binding to 
the TNF receptor, p55TNFR-1, suggesting that blockade of this interaction would result 
in a similar phenotype to C57-ADAM10B-/- lymph nodes [103].  LTβ deficient mice, 
however, experience more mild disruption as they retain mesenteric and cervical lymph 
node development and maintain B/T segregation, FDC networks, and germinal center 
formation in spleen [104].  Thus far, no reports have been made about the contribution 
of B cell specific LTα or LTβ to secondary lymphoid tissue architecture.  More similar to 
LTα deficient mice, global TNF knockouts lack FDC networks in B cell follicles and fail to 
form germinal centers post immunization [32,188,189].  Furthermore, it is known that 
without TNF or its receptor p55TNFR-1, B cell follicles and FDC networks fail to form in 
peripheral lymph nodes, Peyer’s patches, and spleen; however, the effects of B cell 
TNF overexpression had not  been previously reported [32,33].  The role of B cell TNF, 
specifically, in architecture maintenance has been elucidated using a B cell mutant 
model only capable of expressing mTNF.  Without B cell sTNF production, there is loss 
of a proper cortico-medullary junction, reduced germinal center formation, impaired FDC 
network development, and reduced IgG production against T dependent antigens [34].  
While it is known that lack of B cell TNF causes aberrant architecture, this study is the 
first to describe that excessive B cell TNF also leads to defects in secondary lymphoid 
tissue architecture.         
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Because p55TNFR-1 binds both TNF and LTα3, it is reasonable to conclude that 
excessive TNF could outcompete LTα3 for binding to this receptor, resulting in noted 
defects in B/T segregation.  Furthermore, it has been shown that increased sTNF 
contributes to HEV neogenesis [190].  Excessive B cell TNF, therefore, could explain 
the induction of increased cortical HEV neogenesis resulting in increased T cell 
recruitment via CCL21/CCR7 interactions and ultimate aberrancies in B/T segregation 
(Figure 7).  Furthermore, Weskamp et al. recently demonstrated that ADAM17 is critical 
for neovascularization using a conditional knockout model where ADAM17 was 
selectively deleted from endothelial cells and pericytes [191].  Therefore, ADAM17 
overexpression by C57-ADAM10B-/- B cells may be directly involved in increased 
follicular HEVs (Figure 7).  Furthermore, in a Notch-dependent pathway, ADAM17 
overactivation has been implicated in fibroblast activation, excessive collagen formation, 
and fibrosis [192].  Increased ADAM17 in C57-ADAM10B-/- B cells could lead to aberrant 
Notch signaling and increased fibrosis within the lymph node (Figure 7).  Given the pro-
fibrotic properties of ADAM17, our result that ADAM17 overcompensates for ADAM10 
deficiency must be well-considered prior to attempting ADAM10 therapeutic 
neutralization. 
There are two key pieces of data furthering the mechanistic contribution of TNF 
over other ligands.  First, is the recovery of WT architecture in irradiated WT mice 
reconstituted with a 50/50 mix of C57-ADAM10B-/- + TNFKO bone marrow (Figure 12F 
12G).   Compared to high TNF levels noted in WT mice reconstituted with C57-
ADAM10B-/- bone marrow alone (Figure 12B and 12G) or a 50/50 mix of C57-ADAM10B-
/- + WT CD45.1 (Figure 12E and 12G), those reconstituted with a 50/50 mix of C57-
 
 
111 
ADAM10B-/- + TNFKO bone marrow produce an appropriate level of TNF considering 
ADAM10B-/- B cells make too much and TNFKO B cells make none; thus, further 
supporting the mechanistic contribution of TNF.  With the combination C57-ADAM10B-/- 
+ TNFKO model, it is important to note that all cells in the TNFKO do not make TNF, 
which may contribute to the effect seen.  Second, our findings in Balb-ADAM10B-/- B 
cells and lymph nodes indicate that Balb-ADAM10B-/- B cells exhibit only a marginal 
increase in ADAM17 expression (Figure 15) and activity leading to WT levels of TNF 
production, surface expression, and mRNA message levels (Figure 14).  This coincided 
with maintenance of WT lymph node tissue architecture and normal TNF staining within 
B cell follicle regions (Figure 16).   
To conclude, this part of our study demonstrates that compensatory changes in 
ADAM17 expression and function in the absence of ADAM10 is strain dependent and 
more exaggerated in Th1 prone C57Bl/6 mice (Figure 15).  This finding has substantial 
implications in therapeutic design where specific targeting of one ADAM may lead to 
changes in other closely related ADAMs depending on genetic background.  
Furthermore, it is important to study the interaction between ADAM10 and ADAM17 on 
other cell types as well to further elucidate other potential complications.  Lastly, this 
part of our study describes the mechanism underling aberrant secondary lymphoid 
tissue architecture in C57-ADAM10B-/- LNs.   The compensatory increase in B cell 
ADAM17 leads to increased production of B cell TNF, which ultimately underlies 
architectural aberrancies noted in C57-ADAM10B-/- LNs.  Balb-ADAM10B-/- B cells fail to 
increase ADAM17 and TNF production and retain WT architecture characteristics.  This 
finding lends new insight to the discussion regarding how B cell TNF homeostasis is 
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critical for secondary lymphoid tissue organization and how a proper B cell 
ADAM10/ADAM17 ratio is needed to ultimately control TNF signaling.   
1.6.2. Increased B cell ADAM10 and reduced ADAM17 and TNF is predicative of 
increased susceptibility to Th2 responsiveness 
Compelling evidence, herein, demonstrates that B cell ADAM10, ADAM17, and 
TNF are differentially regulated in Th1 and Th2-dominated immune responses and 
directly influences host susceptibility to allergy and IgE production.  We demonstrate 
that Th2 prone mouse strains (Figure 17) and humans (Figure 21, Table 5) exhibit 
increased B cell ADAM10 and IgE, while concomitantly having reduced ADAM17 and 
TNF (Figure 17 and 21).  With regards to mouse strains, we described above that Th 
environment is critical for ADAM17 and TNF regulation in the absence of ADAM10 as 
Balb-ADAM10B-/- are less adept at increasing ADAM17 and thus, TNF cleavage (Figure 
14 and 15) [31].   
A critical question is whether the B cell ADAM10 level is strictly determined by T 
cell help or is an inherent characteristic of B cells from Th1 or Th2 prone strains.  The 
answer is both.  T cell help as demonstrated by in vitro culture with equal concentrations 
of anti-CD40/IL-4 shows that B cell ADAM10 increases in both C57 and Balb WT B cells 
following stimulation (Table 4, Figure 17).  Thus, T cell help augments ADAM10 
expression.  Importantly, however, Balb WT B cells exhibit increased ADAM10 in the 
naïve state and even more dramatically increased ADAM10 after anti-CD40/IL4 
stimulation compared C57-WT B cells (Table 4).  This finding indicates an innate 
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difference between their B cells that affects their sensitivity to T cell mediated ADAM10 
induction.     
Next, regulation of ADAM17 and its ligand, TNF, in different Th contexts was 
analyzed. C57-WT B cells demonstrated increased ADAM17 in naïve B cells and 
increased TNF expression following in vitro stimulation compared to Balb-WT B cells 
(Figure 14).  These B cell differences in the classic Th1 and Th2-biased strains 
extended to other strains of mice as well.  For our studies, we used SJL/J and C57Bl/6 
as our Th1 prone strains and A/J and Balb/c as our Th2 prone strains (Figure 17).  
Furthermore, Th context is critical for understanding the difference in ADAM17 and TNF 
regulation following B cell ADAM10 deletion (Figures 14 and 15), as Balb-ADAM10B-/- B 
cells fail to increase ADAM17 and TNF production, thus permitting WT architecture 
maintenance (Figure 16).  Our evidence suggests that regulation of B cell ADAM10 and 
ADAM17 is determined by both Th context (e.g. T cell help) and inherent differences in 
B cell responsiveness.   
We next described how both Th context and B cell ADAM10 level are critical 
when determining susceptibility to airway hypersensitivity induction in mice.  Our lab 
had previously used an OVA-induced airway hypersensitivity model, which showed a 
reduction in disease parameters in C57-ADAM10B-/- mice including airway resistance, 
OVA- specific IgE, mucus production, and eosinophil infiltration [180].  Using a more 
clinically relevant HDM model, herein, we directly compare C57 and Balb ADAM10B-/- 
mice and both experienced significantly less bronchoconstriction, goblet cell metaplasia, 
mucus, and HDM-specific IgE production (in Balb/c) compared to their respective WT 
strain (Figures 19 and 20).   Importantly, however, Balb- ADAM10B-/- mice had lung 
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inflammation parameters comparable to WT-C57 mice, while C57-ADAM10B-/- had the 
lowest disease induction.  Furthermore, while clinically relevant features of human 
asthma including antigen-specific IgE, mucus, and airway resistance were clearly 
enhanced in an ADAM10 dependent manner, eosinophil infiltration was strain 
dependent only as Balb/c mice regardless of ADAM10 level had increased eosinophil 
counts compared to C57 WT and C57-ADAM10B-/- mice (Figure 19).  This finding does 
not detract from the potential use of ADAM10 inhibitor therapy, however, because 
blockade of eosinophil infiltration by anti-IL-5 monoclonal antibodies alone failed to 
reduce asthma related symptoms in most allergic patients [193,194].  Overall, the data 
indicates that B cell ADAM10 plays an important role in this Th2 disease model with the 
highest ADAM10 expression indicating worst symptomology.   While the mechanism by 
which ADAM10 levels influence Th2 disease is unknown, a candidate mechanism could 
be that ADAM10-mediated CD23 shedding increases IgE production, thus enhancing 
IgE cross-linking and mast cell degranulation [30].  If further validated in a larger human 
cohort study, ADAM10 level could serve as a potential indicator of the directionality or 
strength of a Th1 or Th2 response, with high ADAM10 level indicating a propensity 
toward enhanced Th2 responsiveness with excess IgE production.   
Our data in mouse strains was validated by our findings in active allergic rhinitis 
patients (Th2 prone) who demonstrated increased B cell ADAM10 and reduced B cell 
ADAM17 and TNF production (Figure 21).  Furthermore, increasing B cell ADAM10 
level correlated with increased antigen-specific IgE production (Table 5).  Together this 
suggests that B cell ADAM10 screening could effectively stratify allergic from non-
allergic patients and potentially for their susceptibility to more severe disease.  An 
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appropriate, cost-effective means to perform this task is used herein: flow cytometric 
analysis of ADAM10 levels on peripheral blood CD19+ B cells obtained from a minimally 
invasive venous puncture.  Furthermore, while ADAM10 screening could be a critical 
diagnostic tool, ADAM10 inhibition therapy is an attractive alternative to other commonly 
used therapies as it would inhibit the initial step in the allergic cascade: IgE production.  
We demonstrate, herein, that B cell ADAM10 deletion reduces antigen-specific IgE 
production (Figure 19).  Consequently, ADAM10 inhibitors have the potential to provide 
anti-allergic prophylaxis when locally administered (e.g. inhaler) particularly to atopic 
patients with high B cell ADAM10.   
 Allergic patients with increased B cell ADAM10 concomitantly had reduced B cell 
ADAM17 and TNF, which could also provide mechanistic insight into their enhanced IgE 
production.  Increased B cell TNF production, as seen in aging B cells, limits antibody 
production, suggesting a potentially protective role of ADAM17 and TNF from induction 
of an allergic phenotype [108].  Our findings, overall, suggest that allergy-prone B cells 
display an ADAM10hi/ADAM17lo/TNFlo phenotype, with greater risk of atopic 
manifestations in Th2-biased environments.  Our results are an advance in elucidating 
the key role of ADAM10 in allergy pathogenesis, and provide a novel approach to the 
diagnosis, prognosis, and treatment of atopic disorders. 
1.6.3. C57-ADAM10B-/-mice exhibit decreased antibody production, which may be 
explained by an increased percentage of B10 cells and increased Tregs 
The second immune system alteration in C57-ADAM10B-/- mice described by 
Chaimowitz et al. was a reduction in antigen-specific class switched antibody production 
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post immunization with T dependent antigen.  Unlike the difference in secondary 
lymphoid tissue architecture, both C57 and Balb-ADAM10B-/- mice have reduced antigen 
specific antibody production post NP-KLH immunization (Figures 4, 5, and 13).  
Therefore, increased B cell TNF production cannot be the mechanism underlying this 
alteration because Balb-ADAM10B-/- mice do not exhibit increased TNF.  We, therefore, 
looked into other possible factors that may affect antibody production including a 
regulatory B cell phenotype and Treg influence. 
B10 cells are a unique subset of B cells that have only recently been described 
[145,146].  B10 cells are IL-10 producing B cells, of which only a subset becomes 
antibody-secreting cells [164].  Herein, we demonstrate that following in vitro activation, 
30% of C57-ADAM10B-/- B cells become IL-10 expressing B cells compared to only 10% 
of WT B cells (Figure 22A), which corresponded to increased soluble IL-10 production 
as well (Figure 22B).  Furthermore, IL-10 message was increased 6 fold in C57-
ADAM10B-/- B cells following in vitro stimulation (Figure 22C).  While the topic is 
controversial, some reports state that B10 cells enhance Treg development and 
maintenance [161–163].  Our finding of increased IL-10 in the circulation of C57-
ADAM10B-/- mice (Figure 22E) further supported a potential induction of Tregs, given 
that B cells alone are not thought to make that much IL-10.   
Tregs were in fact increased in C57-ADAM10B-/- spleens (Figure 23 and 24).  
Candidate mechanisms for this Treg enhancement include increased B cell production 
of ICOSL and/or IL-10.  ICOS-ICOSL interaction is critical for the development and 
persistence of Tregs [113,114].  ADAM17 is known to downregulate membrane-bound 
ICOSL and increase soluble ICOSL (sICOSL) production by an indirect mechanism 
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[112].  Given that C57-ADAM10B-/- B cells have increased ADAM17, this suggests that 
increased sICOSL production may enhance ICOS receptor signaling on T cells, thus 
inducing FoxP3 expression in a larger subset of T cells.  ICOSL was increased in naïve 
C57-ADAM10B-/- B cells and thus there is more to be cleaved following ADAM17 
activation (Figure 25).  Preliminary data suggested that neutralization of ICOSL in co-
cultures of CD4+CD25- T cells and C57-ADAM10B-/- B cell supernatants reduced FoxP3 
expression compared to treatment with C57-ADAM10B-/- B cell supernatant alone 
(Figures 27and 28).   Further studies are needed to confirm that neutralization of 
ICOSL signaling in vitro inhibits FoxP3 induction in CD4+CD25- cells.  While IL-10 is not 
thought to induce FoxP3 expression, it is known to be critical for maintaining FoxP3 
expression [195].  Therefore, it is likely that increased IL-10 production by C57-
ADAM10B-/- B cells supports FoxP3 expression, which was increased initially by an 
alternate source (e.g. ICOSL).  IL-10 neutralization experiments should demonstrate a 
reduction, even if slight, in FoxP3 expression following stimulation with WT or C57-
ADAM10B-/- B cell supernatants.  Furthermore, inhibition of both ICOSL and IL-10 
together should cause the largest suppression of FoxP3 induction in CD4+CD25-/B cell 
supernatant co-cultures.  
While studies in Balb-ADAM10B-/- still need to be performed, increased Tregs in 
C57-ADAM10B-/- mice contributed to decreased class-switched antibody production and 
reduced lung inflammation parameters following HDM challenge.  Treg depletion in vivo 
led to enhanced HDM-specific IgE production in both WT and C57-ADAM10B-/- mice as 
well as increased AHR, BALF cellularity, inflammatory cellular infiltration in airways, and 
mucus (Figure 28, 29, and 30).  Therefore, Tregs do play a mechanistic role in limiting 
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class-switched antibody production and lung inflammation in C57-ADAM10B-/- mice.  To 
validate our findings as a Treg-specific phenomenon, we must still confirm Treg 
depletion by flow cytometry.  In Setiady et al. anti-CD25 treatment decreased 
CD25+FoxP3+ cells from 6.5% to 0.7%, although FoxP3+ cells only decreased from 
3.3% to 2.3% [186].  Furthermore, control Rat IgG1 treatment failed to reduce 
CD25+FoxP3+ cells from WT levels [186].  We expect to demonstrate similar results.         
Furthermore, our findings herein may further the understanding of B10 cells 
including their relationship to Tregs and other, un-reported surface markers.  Our data 
suggests that ICOSL and CD43 may be potential markers of B10 cells.  To prove this 
point, co-staining with B220, IL-10, and ICOSL or CD43 is needed to show if IL-10 
producing B cells specifically upregulate these markers compared to non-IL-10 
producing B cells.  
Lastly, the overarching goal of section 1 was to define the immune system 
alterations in B cell specific ADAM10 deficient mice and determine how differential 
ADAM10 levels affects Th2 disease.  Ultimately, we aimed to determine if ADAM10 
inhibitor therapy would be beneficial in treating allergic diseases and if so, by what 
potential mechanism.  Previously, we mentioned that ADAM10 inhibitor therapy for Th2 
disease was a unique way to regulate IgE production.  Our recent findings suggest that 
a potential mechanism by which ADAM10 inhibitors may reduce IgE is through 
enhancement of Treg cells downstream of enhanced B cell ICOSL or IL-10 production.  
It is important to note that ADAM10 inhibitor therapy, however, would not be B cell 
specific and could cause off-target effects.  An i.v administered dual ADAM10/17 
inhibitor has been evaluated in human clinical trials for its anti-neoplastic effects and 
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was found to be well tolerated [196]. While it lacked efficacy in blocking tumor growth, 
our data suggests that locally administered ADAM10 inhibitor therapy (e.g. inhaler) to 
the airway may be preventative against important disease parameters such as 
bronchoconstriction and mucus production and should be further explored.     
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Section 2: Impaired immunological synapse in sperm associated antigen 6 
(SPAG6) deficient mice 
Chapter 1: Introduction to SPAG6 and its role in microtubule rearrangement 
2.1.1 SPAG6 
Mammalian sperm associated antigen 6 (SPAG6), or its orthologue, PF16 
protein, from Chlamydomonas reinhardtii, is classically known as a component of the 
central apparatus of the “9+2” axoneme, which consists of a central pair of microtubules 
(C1 and C2) surrounded by nine outer microtubule doublets with associated dynein 
arms [175,197–199].  Mutagenesis of Chlamydomonas PF16 results in flagellar 
paralysis and disturbance of C1 central microtubule stability revealing its central role in 
flagellar stability and motility [199].  In mammals, SPAG6 is widely expressed, mainly in 
tissues with cilia-bearing cells including lung, nervous system, inner ear, bone marrow, 
and particularly, testicular germ cells where SPAG6 resides in the sperm flagella 
[197,200].  Many of the noted abnormalities associated with SPAG6 deficiency are 
related to dysfunctional ciliary or flagellar appendages in ciliated cells and tissues. In 
humans, SPAG6 in the sperm tail is targeted by a class of anti-sperm autoantibodies 
associated with immune-mediated infertility in males [200].  Global SPAG6-deficient 
mice (Spag6KO) exhibit significant defects including a high percentage of neonatal 
deaths, hydrocephalus, and infertility in surviving male mice [198]. They also experience 
a significant reduction in axoneme numbers and the two central microtubules exhibit a 
random orientation compared to WT mice [201]. Furthermore, Spag6KO tracheal 
epithelial cells lose their polarized morphology and polarized distribution of mucin; and 
these phenotypes appear to be related to a disrupted microtubule system [201].  In 
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addition, Spag6KO mice develop otitis media more readily than WT given abnormalities 
in the ciliated columnar epithelium in the middle ear and Eustachian tube [202].  While 
these examples demonstrate the importance of SPAG6 in ciliated tissues, the role of 
SPAG6 in cells lacking classic cilia and/or flagella, such as lymphocytes or other 
immune cells, remains unreported.  Another protein critical for ciliogenesis, IFT20, has 
been shown to be important for microtubule organization and T cell receptor (TCR) 
recycling at the immunological synapse [203,204].  Therefore, given the contribution of 
SPAG6 protein to microtubule organization, and the critical role of microtubule 
organization in cognate immune cell interaction, we sought to analyze the role of 
SPAG6 in the formation of the immunological synapse as well as the impact of SPAG6 
deficiency on the immune response.  
2.1.2 SPAG6 and its role in the MTOC 
The microtubule organizing center (MTOC) is a subcellular apparatus that 
functions to form and organize microtubules, which in eukaryotic somatic cells is the 
centrosome, composed of two orthogonally arranged centrioles (mother centriole and 
daughter centriole) [205,206].  During an immune response, upon cognate recognition 
between an antigen presenting cell and effector cell, reorientation of the centrosome, 
actin, the Golgi, and secretory vesicles occurs in the effector cell at the immunological 
synapse, allowing receptor/ligand interactions and targeted release of cytokines [207].  
Furthermore, during targeted killing by an effector cell, the same reorientation occurs 
with docking of the centrosome at the synapse membrane of the effector cell, effectively 
creating the synaptic cleft by which cytolytic enzymes are released for targeted 
destruction [205,208]. While SPAG6 is known to be a microtubule-binding protein [197] 
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and co-localizes with polymerized microtubules [209], we demonstrate, herein, the 
expression of SPAG6 protein in primary and secondary lymphoid tissues, its association 
with the centrosome, and the lack of centrosome polarization and actin clearance at the 
synaptic cleft of SPAG6 deficient mice. In addition, we show that these synaptic 
malformations are associated with reduced CTL cytotoxicity, diminished follicular CD4 T 
cell retention in germinal centers, defective germinal center reactions, low production of 
class-switched antibodies, and expansion of the B1 B cell subset. 
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Chapter 2: Materials and Methods 
2.2.1 Mice 
Mice were housed in the Virginia Commonwealth University mouse vivarium in 
accordance with NIH guidelines. All animal care and experimental protocols were 
approved by IACUC. Spag6KO mice were generated as previously described [198] and 
compared to WT littermate controls. C57/SV129 WT male mice age 6-8 weeks were 
used for reconstitution. 
2.2.2 Bone Marrow Reconstitution  
C57/SV129 WT were pretreated with 100 mg/L enrofloxacin for 5 days prior to 
irradiation.  C57/SV129 WT were anesthetized using 80 mg/kg ketamine and 8 mg/kg 
xylazine in PBS and given two doses of 550 cGy irradiation, with a 2-h rest period, using 
a MDS Nordion Gammacell 40 research irradiator with a [137Cs] source.  Bone marrow 
cells were isolated as previously described [169] (see section 1.2.10) and 5 million cells 
i.v. injected into irradiated WT.  After 6 weeks, mice were footpad and i.p immunized 
with 10 µg 4-hydroxy-3-nitrophenylacetyl coupled to keyhole limpet hemocyanin at a 
ratio of 27:1 (Bioresearch Technologies) in 4 mg alum.  Mice were bled at day 7 and 
organs harvested at day 14.   
2.2.3 Reagents and T cell culture 
Spleen was crushed, filtered, RBCs lysed with ACK Lysing Buffer (Quality Biological), 
and  cytotoxic T cells isolated from splenocytes by PE-positive selection using CD8-PE 
(Biolegend) and EasySep kit (Stemcell Technologies).  T cells were grown in complete 
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RPMI [31] with 100 Units/mL IL-2 (Peprotech) on overnight anti-CD3ε (1µg/mL, 
Biolegend) treated plates with anti-CD28 (2µg/mL, Biolegend) and supernatants 
collected for IFN-y ELISA (eBioscience) after 72 h of growth.  Proliferation was 
assessed after 72 h with a 24-h pulse of [3H] thymidine, 1µCi/well (Perkin Elmer). using 
Filtermate cell harvester onto UniFilter-96 GF/C microplates and analyzed by TopCount 
Plate Counter (Perkin Elmer).  
2.2.4 ELISA 
NP-specific antibody  
NP-specific IgM and IgG1 was determined by NP-specific ELISA using NP-14–BSA (15 
µg/ml; Biosearch Technologies) as previously described in section 1.2.6.  
IFNy  
Soluble IFN-y from T cell supernatants was determined by mouse quantitative ELISA kit 
(88-7314-77, eBioscience) according to manufacturer’s protocol.  
2.2.5 Flow cytometry  
Single cell suspension of splenocytes, lymph node, and peritoneal lavage cells were 
incubated with Fc blocking reagent (10 µg anti-mouse unlabeled CD16/32 (2.4G2)); 
stained with B220-APC or PeCy5, CD3-PE or PECy7, CD11b-FITC, or GL7-FITC 
(Biolegend), washed, examined on a BD Canto Flow analyzer, and data analyzed with 
FCS Express, v. 4.   
2.2.6 Cytotoxic assay 
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CD8+ T cells effector cells were isolated from spleen using EasySep mouse PE 
selection Kit (Stemcell Technologies) with CD8-PE (Biolegend).  CD8 T cell purity was 
verified (95-98%) and cultured with platebound anti-CD3ε and anti-CD28 as described 
above in T cell media for 2 days and then seeded into fresh media daily and used 6 
days later.  P815 (ATCC) target cells were grown in complete RPMI.  Cytotox 96 Non-
Radioactive Cytotoxicity Assay (Promega) was used to first determine P815 optimal cell 
concentration (1.2 x 105cells/mL) and then cytotoxicity assay was performed in 
quadruplicate.   
2.2.7 CTL induction and slide set up for synapse staining 
Balb/c WT spleen was collected, crushed, RBC lysed, resuspended to 107/mL, 
and irradiated at 3000rad.  Cells were then counted, washed in T cells media (RPMI 
supplemented with 10% FBS, 50µM β-mercaptoethanol, L-glutamine, sodium pyruvate, 
and 50U/mL penicillin and streptomycin), resuspended to 1.25x106/mL, and 1mL of 
Balb/c stimulator cells cultured with 1mL (at 1.25x106/mL) of WT or Spag6KO responder 
cells for 5 days.  Live cells were collected, washed, and resuspended to 1x106/mL in IL-
2 (100U/mL, Peprotech) supplemented T cell media.  Cells were cultured 5 days and 
seeded into fresh IL-2 supplemented media daily.   
Chamber slides (Thermo Scientific, no. 154534) were coated with ICAM-Fc 
(1µg/mL) in sterile BBS overnight at 4°C.  WT or Spag6 (three per group) CTLs and 
P815 were resuspended to 4x106/mL. 125µL of CTL and P815 were incubated 
separately at 37°C for 5 minutes, mixed, incubated again for 5 minutes, then diluted to 
1x106/mL in warm T cell media.  Cells were incubated on slides for 10 minutes at 37°C, 
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media removed, ice cold 100% methanol added, incubated for at least 5 minutes, 
methanol removed, and slides dried for 30 minutes at 4°C.  Slides were set up as CTL 
alone, P815 alone, CTL+ P815, or PBS only.  
2.2.8 Immunohisto-, cyto-chemistry, and confocal microscopy 
Ten um OCT-embedded frozen sections of WT and Spag6KO lymph nodes were fixed 
in ice-cold acetone for 10 mins then left to air-dry. The sections were re-hydrated and 
blocked with 2% horse serum, then labelled with 10 µg/ml FITC-conjugated T- and B-
Cell Activation Antigen (clone GL7, BD Biosciences 553666), PE-conjugated Rat Anti-
Mouse CD4 (clone GK1.5, southern biotech 1540-09L ), and Alexa Flour 647-
conjugated rat anti mouse CD21/35 (clone 7E9, Invitrogen Molecular Probes,  
RMCD213521) for 45 mins. Sections were thoroughly washed, mounted with anti-fade 
mounting medium, Vectashield (Vector Laboratories), and cover-slipped. The sections 
were examined with Leica TCS-SP2 AOBS confocal laser scanning microscope fitted 
with an oil plan-apochromat ×40 objective. Three lasers were used: Argon (488 nm) for 
FITC, HeNe (543 nm) for PE, and HeNe (633 nm) for Alexa Flour 647 (shown as 
pseudo-color blue). Parameters were adjusted to scan at 1024 × 1024 pixel density and 
8-bit pixel depth. Emissions were recorded in three separate channels, and digital 
images were captured and processed with Leica Confocal and LCS Lite software. The 
number, size and CD4 content of GCs in the LNs of WT and Spag6KO mice were 
counted and measured, and the average was presented + SD.   
For immuno-cyto-chemistry, WT or Spag6KO splenocytes were co-cultured with 
irradiated Balb/c splenocytes for 5 days, remaining live cells seeded into fresh IL-2 
supplemented cRPMI for 3 days, and then allogeneic CTLs were cultured briefly with 
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P815 target cells.  Cells were transferred to pre-coated (ICAM-Fc, 1µg/mL, R&D) Nunc 
chamber slides (Thermo Scientific) and fixed in cold methanol, left to dry then blocked 
with 2% horse serum. The cells were labeled with rabbit anti α-actin antibody (Sigma-
Aldrich A2066-.2ML) or mouse anti gamma-tubulin (clone GTU-88, Sigma-Aldrich 
T6557-.2ML) for 45 mins then washed. Alexa Flour 488-conjugated Fab’2 fragment 
donkey anti-Rabbit IgG (H+L) (Jackson Immuno-Research 711-546-152) or anti Mouse 
IgG (H+L) (Jackson Immuno-Research 715-546-150) [with minimal cross reactivity to 
horse, mouse, rabbit, goat, human and rat proteins] secondary antibodies were then 
added together with rat anti-mouse CD8a-PE (southern Biotech, 1550-09L) and 
NucRed 647 nuclear stain (Invitrogen, R37113). After 45 mins, the cells were thoroughly 
washed, mounted with anti-fade mounting medium, Vectashield (Vector Laboratories), 
and cover-slipped. The cells were examined with Zeiss Laser Scanning Microscope 
LSM 710 fitted with an oil plan-apochromat ×40, x63, and x100 objectives. Three lasers 
were used: Argon (488 nm) for FITC, HeNe (543 nm) for PE, and HeNe (633 nm) for 
NucRed 647 (shown as pseudo-color blue). Parameters were adjusted to scan at 1024 
× 1024 pixel density and 8-bit pixel depth. Emissions were recorded in three separate 
channels, and digital images were captured. Z stacks running through the 
immunological synapse with 0.40 µm step-size were generated and re-structured into 3-
dimensional snap shots and movies using Zeiss Zen 2012 (Blue Edition) software.  
2.2.9 Centrosome staining 
HEK293-T cells were transfected with SPAG6/pcDNA3 plasmid and 48 hours post 
transfection cells were permeabilized with 1% Triton X-100, blocked, incubated 
overnight at 4°C with a polyclonal anti-SPAG6 and monoclonal anti-γ-tubulin, washed, 
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and incubated for 1 h at room temperature with Alexa 488-anti-mouse IgG (Jackson 
Immuno Research Laboratories) and Cy3-anti-rabbit IgG (Jackson ImmunoResearch 
Laboratories). Finally slides were washed and sealed using VectaMount with 4', 6-
diamidino-2-phenylindole (DAPI) (Vector Laboratories). Images were taken by confocal 
laser-scanning microscopy (Leica TCS-SP2 AOBS). 
2.2.10 RT-PCR  
Total RNA was isolated using TRIzol reagent (Invitrogen), reverse transcribed using 
RETROscript® (Ambion, AM1710), and PCR performed to examine Spag6 mRNA 
expression compared to Gapdh control . The primer set used in our previous study was 
applied [210]. 
2.2.11 Statistical analysis 
Normal distribution of data was determined using Shapiro-Wilk normality test in 
SigmaPlot 12.5.  The p values were calculated using unpaired two-tailed Student t tests 
in GraphPad Prism. Error bars represent the SEM between samples. A p value <0.05 is 
considered significant. 
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Chapter 3: Results and Discussion 
2.3.1 SPAG6 is expressed in primary and secondary lymphoid tissues and co-
localizes with the centrosome  
The expression and role of SPAG6 in immune system development and adaptive 
functions is unknown.  While the murine immune system fails to mature until about six 
weeks of age, the majority of Spag6KO mice survive less than three weeks due to 
numerous developmental defects. Therefore, we first confirmed expression of Spag6 in 
various immune cells and tissues of adult WT mice including spleen, thymus, bone 
marrow, lymph node and naïve T cells by RT-PCR (Figure 33).  In order to study 
SPAG6 loss in a mature immune system, adult WT mice were irradiated and 
reconstituted with 7-14 day old WT or Spag6KO bone marrow.  SPAG6 is known to be 
critical for ciliogenesis and microtubule-based motility [201]; and despite the fact that 
lymphocytes do not have cilia, their engagement with antigen presenting cells and 
target cells involves extensive remodeling of cytoskeletal and motor proteins.  De la 
Roche et al. proposed that the T cell immunological synapse at the interface between T 
cells and antigen presenting / target cells is a “surrogate cilium” because it utilizes the 
same machinery as ciliogenesis including the nucleation of microtubules at the MTOC 
or centrosome [207,211]. De la Roche et al. also described how Hedgehog signaling, 
originally known for its role in primary cilia formation, is also critical for CTL function and 
immunological synapse formation [207]. Consequently, we sought to determine if 
SPAG6 is present in the MTOC or centrosome and, if so, could SPAG6 be required for 
proper immunological synapse formation and function. We previously reported that 
SPAG6 decorated and appeared to organize the microtubules in transfected CHO cells 
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[209], however, whether SPAG6 protein is a structural component of the MTOC or 
centrosome is not known. To explore the SPAG6-centrosome association, HEK293 
cells were transfected with SPAG6/pcDNA3 plasmid and then the cells were double 
labeled with a polyclonal antibody against SPAG6 and a monoclonal antibody against γ-
tubulin, a centrosome component. As shown in Figure 34, SPAG6 co-localized with γ-
tubulin indicating that SPAG6 protein is structurally associated with the 
MTOC/centrosome apparatus.  
2.3.2 SPAG6 is required for centrosome polarization and actin clearance at the 
immunological synapse 
Given that SPAG6 is structurally associated with the centrosome (Figure 34), 
and the centrosome is crucially involved in synapse organization, we predicted that 
SPAG6 plays a critical role in immunological synapse formation.  Two hallmarks of 
adequate synapse formation are centrosome polarization to the synapse and actin 
clearance from the synapse [207].  At the central supra-molecular activation cluster of 
the immunological synapse, the centrosome moves to and contacts with the plasma 
membrane, whereas actin is cleared away from the synapse.  It has been proposed that 
centrosome polarization might be driven by the reorganization of the actin cytoskeleton, 
clearing the plus ends of microtubules from the area of contact and pulling the 
centrosome towards the plasma membrane [212].  To analyze the role of SPAG6 in 
synapse formation, allogeneic CTLs were cultured briefly with P815 target cells, then 
labeled for α-actin and γ-tubulin to visualize the synaptic cleft at the interface between 
CTLs and their targets. Figure 35 A, C demonstrates that SPAG6 is required for actin 
clearance at the synapse as lack of SPAG6 in Spag6KO CD8 T cells was associated 
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with inefficient  actin clearance and persistence of actin staining at the synapse.  On the 
other hand, WT CD8 T cells efficiently cleared actin at the synapse and labeling showed 
an actin ring distal to the synapse.  Movies constructed from z stacks passing through 
the whole depth of the synapses confirmed lack of actin clearance in Spag6KO mice 
and efficient regression in the WT mice (data not shown). Actin reorganization is 
thought to play a role in centrosome polarization [212], consequently, lack of SPAG6 
also resulted in improper polarization of the centrosome and lack of positioning at the 
synapse (Figure 35 B, C).  Specifically, in WT CTL cells, centrosome docking at the 
synapse occurred in 50% of CTL/target cell synapses with only 10% positioned distal to 
the synapse; whereas, Spag6KO CTLs exhibited centrosome docking in only 30% of 
synapses (Figure 35C).  Furthermore, the majority of centrosomes were docked or 
proximal to the synapse in WT CD8 T cells compared to Spag6KO CD8 T cells where 
the majority were distal or proximal to the synapse, with fewer docked (Figure 35C).   
2.3.3 Reduced T cell cytotoxicity in Spag6KO 
Thus far, we have determined that SPAG6 is expressed in primary and 
secondary lymphoid tissues (Figure 33), co-localizes with the centrosome (Figure 34), 
and its deficiency is associated with defective centrosome polarization and actin 
clearance (Figure 35) suggesting that these structural abnormalities will obstruct proper 
functional communication at the synapse site, which can be assessed by analyzing 
cytotoxic T cell (CTL) killing of target cells and T cell-dependent class-switched antibody 
production in WT and Spag6KO mice.   
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CTLs destroy target cells following T cell receptor activation through release of 
secretory lysosomes at the immunological synapse. T cell receptor activation triggers 
migration of the MTOC to the contact site, causing the generated microtubule network 
to polarize towards the target [208]. Secretory lysosomes then travel in a minus end 
direction toward the MTOC [208] followed by transient fusion of the centrosome with the 
plasma membrane to mediate secretion into the synapse [212]. Given the presence of 
SPAG6 in the centrosome, we reasoned that in the absence of SPAG6, reduced CTL-
induced cytotoxicity would occur. We performed an allogeneic cytotoxic T cell assay 
and demonstrated that Spag6KO T cells had significantly reduced capacity to induce 
P815 cell death compared to WT CD8 T cells (Figure 36A). Furthermore, stimulated 
Spag6KO CD8 T cells had reduced secretion of soluble IFNγ (Figure 36B). These 
findings are not due to reduced T cell number (Figure 36C) or their ability to proliferate 
(Figure 36D). In fact, Spag6KO CD8 T cells cultured with anti-CD3/CD28 exhibit 
enhanced proliferation compared to WT CD8 T cells (Figure 36D), suggesting an even 
greater reduction in IFNγ secretion per cell than is suggested in Figure 36B.  
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Figure 33. SPAG6 expression in lymphoid cells and tissues.  
Spag6 expression in adult WT mice compared to testis (positive control) and negative 
control (water). Spag6 is expressed in primary (thymus, bone marrow) and secondary 
(spleen, lymph node) lymphoid tissues and T cells. 
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Figure 34. Presence of SPAG6 protein in the centrosome.  
 
HEK293 cells were transfected with SPAG6/pcDNA3 expressing plasmid, and the cells 
were stained for DAPI (blue), SPAG6 (red) and γ-tubulin (green), a component of 
centrosome. Co-localization of SPAG6 and γ-tubulin is indicated by white arrows.  
Figure courtesy of Dr. Zhibing Zhang.   
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Figure 35. Defective actin clearance and centrosome polarization at the 
immunological synapse in Spag6KO mice.  
(A, B) The immunological synapse between WT or Spag6KO CD8+ CTLs (red) and 
P815 target cells was stained for (A) α-actin (green, white arrows, upper panel) or (B) γ-
tubulin (green dots, white arrows, lower panel). (C) Quantification of actin clearance 
(left) and centrosome (γ-tubulin) polarization and docking distance from the synapse in 
WT and Spag6KO CD8+ cells shown. P values shown. 
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Figure 36. Reduced CTL function in Spag6KO mice.  
 
(A) Allogeneic cytotoxicity assay with decreasing ratios of WT (solid) or Spag6KO 
(dashed) CD8+ T cells to P815 target cells; (B) Soluble IFNγ production by WT or 
Spag6KO CD8+ T cells  (C) CD3+ T cell percentage of total splenocytes; gated from 
live singlets. (D) WT or Spag6KO (KO) CD8+ T cell proliferation in media alone (white) 
or with CD3/CD28 stimulation (stripes). N=3-7 per group; **p<0.005, ***p<0.0005. 
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2.3.4 WT mice reconstituted with SPAG6 deficient bone marrow exhibit impaired 
GC formation, diminished follicular CD4 T cells, reduced class-switched antibody 
production, and expansion of B1 B cells 
Establishment of a proper immunological synapse is required for optimal 
antibody production as well. A series of synapses is generated to mount an effective 
humoral immune response. First, a synapse between cognate antigen-specific B and T 
cells occurs at the B/T border to trigger downstream GC formation.  Furthermore, 
synapse formation and signaling between B cells and Tfh cells is required for class 
switch recombination and affinity maturation [213]. Moreover, BCR engagement with 
FDC-retained antigens is critical for GC persistence and selection of high affinity B cell 
clones [214]. We, therefore, hypothesized that Spag6KO mice, who have a comparable 
number of B cells to WT (data not shown), would exhibit impaired GC formation and 
reduced class-switched antibody production post immunization with T cell-dependent 
antigens.  Following immunization with the T cell-dependent NP-KLH antigen, the 
germinal center reactions and CD4+ T cells in the draining LNs were assessed in WT or 
Spag6KO reconstituted mice.  Following 14 days of immunization, the number and size 
of GCs in the follicle were significantly reduced in Spag6KO (Figure 37A).  
Furthermore, the number of GC CD4+ T cells were significantly diminished, suggesting 
reduced migration of Tfh cells to the GC perhaps due to lack of initial 
signaling/interaction with the B cell, or due to impaired retention in the GC due to lack of 
effective GCB cell/T cell synapse (Figure 37A).  In fact, stable GC-B cell/T cell 
interaction is critical for selection of antigen-specific B cells, B cell activation and plasma 
cell differentiation, and this interaction is associated with reduction in both GCB and Tfh 
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cell velocities, along with an increase in the duration and size of the T-B contacts 
[84,215–218].  
 The reduction in GC formation and CD4+ T cells in Spag6KO mice 
corresponded with significantly reduced NP-specific IgG1 production on day 14 (Figure 
37B, right).  While NP-specific IgM and IgG1 levels were comparable at day 7 post 
immunization (data not shown), NP-specific IgM is increased in Spag6KO serum at day 
14 (Figure 37B, left).  This result could be attributed to increased extrafollicular 
antibody production in Spag6KO B2 cells or perhaps due to the increase in peritoneal 
B1 B cells (Figure 37C).  B1 B cells are innate, self-renewing, long lived B cells, which 
typically reside in the peritoneal and pleural cavities as well as spleen [219].  They fail to 
enter germinal centers, are thought to make natural antibodies, and do not require 
cognate T cell interaction for IgM production [219].  Our noted increase in B1 B cells in 
the absence of SPAG6 suggests that SPAG6 is involved in attenuating the B1 response 
and may be an interesting target for limiting autoimmune reactions, as increased B1 B 
cells are related to predisposition to autoimmunity [220,221].  
In conclusion, while classically studied in ciliary and flagellar motility, SPAG6 is 
expressed in primary and secondary lymphoid tissues and its role in immune system 
development and function stems from its critical role in proper immunological synapse 
formation. We provide novel and substantial evidence that SPAG6 is present in the 
centrosome and is required for optimal centrosome polarization and actin clearance 
during synapse formation. SPAG6 deficiency is associated with inadequate synapse 
formation manifested by significant functional consequences including reduced CD8 
cytotoxicity, CD8 T cell IFNγ secretion, GC formation, GC CD4+ T cell retention, and 
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class-switched antibody production. These structural and functional abnormalities were 
associated with an increase in B1 B cell subset numbers. Finally, original data 
presented in this study paves the way for new investigations on the role of SPAG6 in 
synapse-dependent immunological interactions and the impact of SPAG6 targeting by 
autoantibodies in immune infertility on cellular and humoral immune responses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37. Defective humoral immune response in 
 
(A) Reduced GC formation and GC CD4+ T cells in draining LN (day 14) of WT (left) 
and Spag6KO (right) reconstituted mice. GCs (GL7+, green), FDCs (CD21+, blue), and 
CD4 T cells (red) are shown. On the top, triple overlay (left) and separate channel 
recordings (right) shown for WT and 
least 6 sections per group showed reduced number and size of GCs and CD4+ T cells 
per GC in Spag6KO. Day 14 NP
sera. (C) Percentage of peritoneal B1 B cells (B220+CD11b+) collected at day 14. N=9 
per group, 3 independent experiments. *p<0.05, **p<0.005.
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SPAG6KO mice. 
Spag6KO.  Below, GC morphometric analysis of at 
-KLH specific (B, left) IgM and (B, right) IgG1 levels in 
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